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Abstract 
 
The apoptosis is a highly regulated programmed cell death that is important for 
maintaining the integrity and homeostasis of multicellular organisms. Conversely, 
deregulation of apoptosis, resulting in either less or excessive cell death, is associated 
with several pathologies including cancer. The intracellular machinery responsible for 
apoptosis is dependent on a family of proteases that have a cystein at their active site and 
cleave their target proteins at specific aspartic acids, called caspases. Thus, modulators 
of these proteins may represent a promising therapeutic strategy against apoptosis-
related diseases. 
Flavonoids represent an interesting class of naturally occurring compounds that 
have been attracting attention of the scientific community because of their wide range of 
biological properties, being the antitumor activity one of the most studied. The antitumor 
activity of flavonoids is associated, at least in part, to their ability to induce apoptosis by 
affecting the expression or activity of a wide variety of molecules involved in apoptosis 
pathways. Additionally, this class of secondary metabolites has shown to be activators of 
caspases. 
In order to improve the antitumor effects and to study the influence of alkylation of 
the flavonoid scaffolds on this activity, we have proposed to develop alkylated flavonoids 
with enhanced antitumor activity. Accordingly, in this work we described the synthesis of 
twenty-six alkylated derivatives (eighteen flavones and eight flavonols) of three natural 
flavonoids (baicalein, 3,7-dihydroxyflavone and chrysin). On the basis of our current state 
of knowledge sixteen from these twenty-six alkylated flavonoids are described for the first 
time. 
The synthesis of alkylated flavonoids was carried out by reacting the building blocks 
with alkylating agents, in alkaline medium using microwave-assisted organic synthesis 
(MAOS). Previously, the suitable amount of alkylating agent to obtain the intended 
alkylated derivatives was determined by a HPLC-DAD study.  
The structure elucidation of the synthesized compounds was established on the 
basis of IR and NMR techniques.  
The ability of three synthesized alkylated flavonoids (Biso1, Brop1 and Bali1) to 
modulate procaspases-3 and -7 activity was evaluated using yeast-based assays. Results 
 x 
 
showed that the monoalkylated derivatives of baicalein Biso1, Brop1 and Bali1 behaved 
as procaspase-7 activators, being Biso1 the most potent compound. 
An in silico docking study was performed using procaspases-3, -6, and -7 as targets, 
and Biso1, Brop1 and Bali1 as potential ligands. In accordance with the results of the 
biological assays, docking studies suggested that Biso1 was the most active procaspases 
activator. 
In summary, the results of this study demonstrate the possibility of obtaining new 
potential procaspase activators through the alkylation of flavonoids derivatives. 
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Resumo 
 
A apoptose é um processo de morte celular programada altamente controlado, 
que é importante para a manutenção da integridade e homeostasia dos organismos 
multicelulares. A desregulação da apoptose, resultando numa deficiência ou exacerbação 
da morte celular, está associada a diversas patologias, incluindo o cancro. A maquinaria 
intracelular responsável pela apoptose é dependente de uma família de proteases que 
têm um resíduo de cisteína no seu local ativo e clivam as proteínas alvo em resíduos de 
ácido aspártico, denominadas caspases. Assim, os moduladores destas proteínas pode 
representar uma estratégia terapêutica promissora contra doenças relacionadas com 
apoptose. 
Os flavonóides representam uma classe de compostos que tem atraído a atenção 
da comunidade científica devido à sua ampla gama de propriedades biológicas, sendo a 
atividade antitumoral uma das mais estudadas. A atividade antitumoral de flavonóides 
está associada, pelo menos em parte, à sua capacidade para induzir apoptose afetando a 
expressão ou a atividade de uma ampla variedade de moléculas envolvidas em vias de 
apoptose. Além disso, estes metabolitos secundários têm mostrado ser ativadores de 
caspases. 
Com o intuito de melhorar os efeitos antitumorais e estudar a influência da 
alquilação dos scaffolds flavonóides nesta atividade, propusemo-nos a sintetizar 
flavonóides alquilados com actividade antitumoral melhorada. Assim, neste trabalho 
descrevemos a síntese de vinte e seis derivados alquilados (dezoito flavonas e oito 
flavonóis) de três flavonóides naturais (baicaleína, 3,7-dihydroxyflavone e crisina). Com 
base no nosso conhecimento atual desasseis destes vinte e seis flavonóides alquilados 
são descrito pela primeira vez. 
A síntese de flavonóides alquilados foi realizada fazendo reagir os blocos 
construtores com agentes alquilantes, em meio alcalino, utilizando síntese orgânica 
assistida por microondas (MAOS). Previamente, foi elaborado um estudo utilizando o 
HPLC-DAD para determinar a quantidade adequada de reagente alquilante para obter os 
derivados alquilados.  
A elucidação estrutural dos compostos sintetizados foi estabelecida com base em 
técnicas de espetrofotometria de infravermelho e ressonância magnética nuclear.  
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Para três flavonóides alquilados sintetizados (Biso1, Brop1 e Bali1) foi avaliada a 
capacidade para modular a actividade das procaspases-3 e -7, utilizando ensaios 
baseados em levedura. Os resultados mostraram que os derivados da baicaleína Biso1, 
Brop1 e Bali1 se comportaram como ativadores da procaspase-7, sendo o Biso1 o 
composto mais potente. 
Um estudo in silico de docking foi realizado utilizando as procaspases-3, -6, -7 
como alvos, e os derivados Biso1, Brop1 e Bali1 como potenciais ligandos. Em 
concordância com os resultados obtidos nos ensaios biológicos, os estudos de docking 
sugeriram que o derivado Biso1 foi ativador mais potente das procaspases. 
Em resumo, os resultados deste estudo demonstram a possibilidade de serem 
obtidos potenciais moduladores da actividade de caspase com base na alquilação do 
scaffold flavonoide. 
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1.1. Outline of the dissertation 
The dissertation is organized in six chapters. 
Charter 1- Outline and Aims of the Dissertation 
The first chapter establishes the aims of the work focusing also on the organization 
of the dissertation, giving a brief description of what will be referred in each chapter. 
Chapter 2- Introduction 
The second chapter deals with the theoretical background that supports the 
developed work and so is sub-divided into two subchapters. The first subchapter is 
focused review about caspases, namely, their structure and classification, modulation of 
caspases activity and pharmacological regulators. A brief review concerning flavonoids, 
including chemistry and the biological activities described for this group of compounds 
particularly their antitumor activity is described in the second subchapter. 
Chapter 3– Results and Discussion 
The third chapter focus on the results and discussion of the developed research 
work, being sub-divided into five subchapters, which deal with the discussion of the results 
obtained concerning the synthesis, optimization of reactions conditions, determination of 
the peck purity, biological activity and docking studies. 
Chapter 4 – Conclusions 
The fourth chapter focus on the main conclusions and future work. 
Chapter 5 - Experimental Procedures  
The fifth chapter refer the synthetic procedures adopted for the synthesis of the 
derivatives of baicalein, 3,7-dihydroxyflavone and chrisin, as well as describe about the 
optimization of reactions conditions. A reference to the procedure used for the evaluation 
of peck purity, biological activity and docking studies is also presented in this chapter. 
Chapter 6 – References 
Herein is presented a list of the references used in this dissertation. 
Chapter 7 – Appendixes 
The seventh chapter includes a table with the structure of all synthesized compounds. 
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1.2. Aims of the dissertation 
 
As a result of the search for new bioactive compounds with antitumor activity by 
CEQUIMED-UP and UCIBIO/REQUIMTE, the prenylflavonoids FP2 (1) and FP11 (2) 
(Figure 1) have been identified as procaspase-7 activators.  
 
 
 
Figure 1: Chemical structures of prenylflavonoids identified as procaspase-7 activators. 
 
 
The main purpose of this dissertation was to obtain more potent procaspase 
activators, using FP2 (1) and FP11 (2) as models by molecular modification of natural 
flavonoids.  
 
Other aims of this research work were: 
 
- to apply non-classic methodologies for the synthesis of flavonoids, namely MAOS; 
- to draw some SAR considerations; 
- to evaluate the effect of the synthesized flavonoids on the executioner 
procaspases activity using yeast-cell based models; 
- to perform doking studies of bioactive compounds with their targeted procaspases-
3, 6 and 7. 
 
 
 
 
 
 
 
 
 
 
                Chapter 2: 
Introduction 
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2.1. Caspases 
 
2.1.1. Structure and classification 
 
Caspases form a cysteine protease/peptidases family that uses the cysteine residue 
as catalytic nucleophile. They share a high specificity to break target proteins in sites after 
aspartic acid residues. The name "caspase" is derived from this characteristic molecular 
function: cysteine-aspartic-acid-proteases.1 
The caspases family consists in fifteen different proteins, being eleven expressed in 
human cells (caspases-1 to -10 and -14).2 They are grouped into two families: the 
inflammatory and apoptotic. However, these proteins are usually classified into three 
subfamilies because apoptotic caspases are subclassified according to their mechanism 
of action.3 Thus, according with their physiologic function, substrate specificity and 
sequencing similarities, they are grouped into three subfamilies: inflammatory (Group I), 
initiator of apoptosis (Group II) and effector/executioner of apoptosis (Group III) 
caspases.2 
The inflammatory caspases are involved in the inflammatory response of the 
cytokines activation, while the initiator and effector/executioner caspases are involved in 
the apoptotic cascade.4 The initiator caspases are the first to be activated in a particular 
death pathway and are the first step for the executioner caspases activation.1 
All the caspases can be found in cells in their inactive form, as zymogen 
(procaspase) precursor. The initiator caspases are present in the cell as zymogen 
monomers and the executioner caspases exist as inactive zymogen dimers.4 These 
procaspases are simple strand proteins, with a variable size N-terminal prodomain, a 
central large subunit, with the cysteine residue active site, and a C-terminal small subunit 
(p10; ~10 KDa). The catalytic domain includes the large subunit (p20; ~20 KDa) and the 
small subunit, which has essential residues for caspases activity (Figure 2).2 
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The Group I, including procaspases-1, -4 and -5, presents a large N-terminal 
prodomain that has a caspases–recruitment domain (CARD), crucial for the formation of 
protein complex that lead to caspases activation (Figure 3). The Group II, including 
procaspases-2, -8, -9 and -10, has a large N-terminal prodomian (>90 amino acids), 
containing a CARD (procaspases -2 and -9) or a death effector domain (DED; 
procaspases-8 and -10) that is important in protein–protein interactions with other 
adaptive proteins (Figure 3). The Group III, including the effector procaspases-3, -6 and -
7, has only a short prodomain of 20-30 amino acids (Figure 3).2  
 
 
 
catalytic domain 
Cleavage site Aps-x Cleavage site Aps-x 
N-terminus  C-terminus 
Prodomain 
(variable size) 
Large subunit  
(p20) 
 
small subunit 
(p10) 
(~10KDa)  
Catalytic Cysteine conserved site 
C 
 
Figure 2: A schematic representation of structural features of human procaspases (C represent the active 
site residue). 
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2.1.2. Caspases activation 
 
Biochemical and structural analysis revealed an underlying conservation of the 
caspases activation process. Additionally, the stabilization process of the proenzyme 
latent state is also conserved.1,5 
The activation of initiator caspases is mediated by dimerization, through “induced 
proximity”, when adaptor proteins interact with the prodomains. However, interdomain 
cleavage, promoted by initiator caspases, is involved in the activation of executioner 
caspases.5,6 
Studies revealed that active initiator caspases are dimers with identical catalytic 
units, where each catalytic unit has one active site. The subunits are derived of only one 
molecular precursor (procaspase) through an internal cleavage in subunits marked sites. 
In fact, it has been demonstrated that this cleavage is neither necessary nor sufficient for 
the initiator and inflammatory caspases activation.4 It is required a dimerization of the 
zymogen monomers to assume an active conformation. The dimerization process occurs 
in a multiprotein activation complex that recruits procaspase through the N-terminal 
recruitment domain (Figure 4).1 
Inflammatory caspases 
Caspases-1, -4 and -5 
 
Initiator caspases 
Caspases-2 and -9 
 
Caspases-8 and -10 
 
Executioner caspases 
Caspases-3, -6 and -7 
 
CARD 
DED 
Large subunit 
Small subunit 
Prodomain 
 
Figure 3: Schematic representation of the domain organization of human procaspases from different 
subfamilies. 
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Concerning executioner caspases, their precursor procaspases are found in the 
cytosol in the inactive dimer form.4 These are activated through limited proteolysis inside 
the interdomain linker, by initiator caspases or occasionally by other proteases in specific 
circumstances (Figure 5).1 
 
 
Effector caspase (inactive dimer-procaspase ) 
Cleavage by Initiator Caspase 
Active Effector Caspase 
Initiator or inflammatory caspase (inactive monomer-procaspase) 
Proximity Induced Dimerization 
Autocleavage 
Active Initiator Caspase 
 
Figure 4: Mechanisms of initiator caspases activation. Dark Blue indicates small subunit, clear blue indicates 
large subunit, green represent prodomain that contains CARD represented by the yellow color. 
 
Figure 5: Mechanisms of effector caspases activation. Dark Blue indicates small subunit, clear blue indicates 
large subunit and the prodomain is represented in green. 
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p20 
p20 
p10 
p10 
C 
C 
Studies of X-ray crystalline structure of some caspases have suggested that 
caspases are present in the dimers form, with two large and two small subunits, like 
heterodimers (p202-p102) (Figure 6).5,7 Each heterodimer subunits are formed from 
hydrophobic interactions that bend into a compact cylinder, dominated by a central strand 
of six β-sheets. The heterodimers interact through a twelve β-sheets which are 
surrounded by five α-helices, distributed in the opposite side of the β-sheets formed site. 
This unique protease structure is almost caspase exclusive. On the caspases 
heterodimers, two of these cylinders align in a head-tail configuration getting the two 
active sites on opposite sides.5 
 
 
Regarding the activation of inflammatory caspases-1 and -5, it occurs in a complex 
named inflammasome (Figure 7). The inflammasome includes procaspases-1 and -5, 
which contains CARD, as well as the NALP-1 protein. This complex formation results in 
the processing and activation of IL-1β and IL-18 cytokines that has a central role in the 
immunity response to microbial pathogens.5 
 
Figure 6: A schematic representation of active caspases structure (C represent the active site residues). 
Dark Blue indicates small subunit and clear blue indicate large subunit. 
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ASC Procaspases -1/-5 
CARD 
PYD 
NACH 
LRR  
FIND 
procaspase -1 
Procaspase -5 
IL-1β  
IL-18 
Pro IL-1β  
Pro IL-18 
Inflammasome 
Caspase -1 
Figure 7: Mechanisms of inflammatory caspases activation. The inflammasome is formed with proteins (such 
as NALP-1 protein) and procasases-1 and -5. The NLR family is characterized by the presence of a central 
nucleotide-binding and oligomerization (NACHT) domain, which is commonly flanked by C-terminal leucine-
rich repeats (LRRs) and N-terminal caspase recruitment (CARD) or pyrin (PYD) domains. Procaspase-1 binds 
to CARD in ASC that which in turn have PYD that is responsible for recruitment with PYD of NLRL-1, and 
procaspase-5 binds to the CARD. Active caspases are released and allows activation of pro IL-11β and pro 
IL-18 in IL-1β and IL-18 cytokines. 
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Intrinsic pathway 
 
Apoptosome 
Procaspase-9 Caspase-9 
Cytochrome c 
Extrinsic pathway 
DISC 
Procaspase-8 
Procaspase-10 
Caspase-8 
Caspase-10 
Procaspase-3 
Procaspase-6 
Procaspase-7 
Caspase-3 
Caspase-6 
Caspase-7 
APOPTOSIS 
2.1.2.1. The caspase pathways 
 
The signal transduction for caspase activation may occur by two main distinct 
pathways: extrinsic, which is a receptor-mediated pathway, and intrinsic, a mitochondrial-
mediated pathway (Figure 8). 5 
 
 
 
 
Figure 8: The caspases pathways: extrinsic and intrinsic. The extrinsic pathway, formed DISC enables the 
activation of caspase-8 and -10, which will activate procaspases-3, -6 and -7. The intrinsic pathway is in 
apoptosome that allows the activation of procaspase-9, which will also activate procaspases-3, -6 and -7. 
Thereby apoptosis is activated.  
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2.1.2.1.1. Extrinsic pathway 
 
The process is initiated by extracellular signals delivered in the form of ligands 
binding to death receptors (DRs).3 DRs are the transmembrane proteins containing an 
extracellular ligand-binding domain and an intracellular death domain (DD), which is 
required for receptors to recruit downstream apoptotic proteins.8 They are members of the 
tumor necrosis factor (TNF) superfamily and include TNF receptor-1 (TNFR1), the FAS 
(also known as CD95 or APO-1), death receptor 3 (DR3), and TNF-related apoptosis-
inducing ligand receptor-1/2 (TRAIL-R1/R2).3,5 The bounding of TNF and other ligands 
with the transmembrane death receptors leads to the recruitment of intracellular adaptor 
proteins (Fas-associated death domain, FADD), which in turn recruit the initiator 
procaspases-8 and 10, forming death-induced signaling complexes (DISC).6 It is inside 
this DISC that the initiator procaspases-8 and -10 are activated through induced proximity 
dimerization (Figure 9).6 
 
Ligands 
FADD 
DRs (TNFR) 
Procaspase-8 
or 
Procaspase-10 
Caspase-8/-10 
Extrinsic pathway 
TNFR1 
FAS (CD95 or APO-1) 
DR3 
TRAIL-R1/R2 
DISC 
Figure 9 : Activation of the extrinsic pathway. 
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The DISC molecules interactions are based in homotypic contacts. The DD of the 
receptor interacts with the DD of the FADD, the DED of the FADD interacts with the DED 
of the procaspases N-terminal and cell inhibitor proteins.8 
The procaspase-8 processing includes two cleavages. The first cleavage occurs 
between the protease domains, where the subunits p43/41 and p10 are formed, remaining 
both the products bounded to the DISC (p43/41 through DED interactions and p10 by 
interactions with proteases large domain). The second cleavage occurs between the 
prodomain and the large subunit. As a result of this cleavage, p43/41 is processed to the 
p26/p24 prodomain and p18.5 Therefore, after the dimerization, the N-terminal DED are 
proteolytically removed and the mature caspase-8 is released to the cytosol, triggering the 
apoptosis process. The same happens with caspase-10.1 After this, caspase-8 and 10 
subsequently activates the downstream executioner procaspases to induce apoptosis.  
 
2.1.2.1.2. Intrinsic pathway 
 
In the intrinsic pathway, several stimuli like oxidative stress, thermal shock, DNA 
damage, among others, trigger the release of mitochondria cytochrome c to the 
cytoplasm, because the mitochondrial outer membrane permeabilization (MOMP) is 
altered.4 
The MOMP is highly controlled primarily through interactions between pro- and anti-
apoptotic members of the BCL-2 protein family. BCL-2 protein family is divided into three 
groups based on their BCL-2 homology domain organization: anti-apoptotic (e.g. BCL-2 
and BCL-XL), pro-apoptocic effectors (e.g. BAX and BAK), and pro-apoptotic BH3-only 
proteins (e.g. BID).9 Activation of BAX and BAK is essential for MOMP.4 The anti-
apoptotic BCL-2/Bcl-xL inhibit BAX and BAK and the BH3-only proteins help in the 
regulation of the balance between the pro- and antiapoptotic proteins (Figure 10).6 
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After the release of cytochrome c (Figure 11A), a cytoplasmic complex with high 
molecular weight, the apoptosome, is formed. It is formed by a central protein known as 
apoptotic protease-activating factor-1 (Apaf-1) that also contains the CARD domain.5 In 
the presence of cytochrome c and ATP, Apaf-1 becomes more linear allowing its 
polymerization.1 In this phase, the procaspase-9 is recruited to the complex through 
interactions between Apaf-1 CARD and procaspase-9 CARD, leading to its activation.6 
The caspase-9 then activates downstream executioner procaspases to induce apoptosis 
(Figure 11, A).1,6 
Beyond the cytochrome c, a secondary mitochondrial activator of caspases/direct 
IAP-binding protein (Smac/DIABLO) is released into the cytoplasm. Smac/DIABLO 
interacts with the antiapoptotic protein X chromosome-linked inhibitor of apoptosis protein 
(XIAP). Caspases-3, -7 and -9 are inhibited by XIAP. Then, if Smac/DIABLO is released, 
XIAP is inhibited and caspases stay active (Figure 11, B).10 
BAX or BAK BID 
BCL-2 or BCL-XL 
Anti-apoptotic BCL-2 proteins 
Pro-apoptotic BCL-2 proteins 
   Effectors 
 
 
BH3-only proteins 
 
 
BH4 
BH3 
BH1 
BH2 
TM 
Activation 
Inhibition 
Directly 
Indirectly 
Figure 10: Anti-apoptotic and pro-apoptotic BCL-2 family. This family can be divided according to their BCL-
2 homology domain organization: the anti-apoptotic BCL-2 proteins (Bcl-2 and Bcl-xL) and two types of pro-
apoptotic BCL-2 proteins, effectors that actually cause MOMP or BH3 only that relay the apoptotic signal to 
the effectors (BAX and BID, respectively). BID active directly BAX or BAK or indirectly by inhibition Bcl-2 or 
Bcl-xL, that to be inhibited loses the ability to inhibit BAX or BAK. 
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The cascade activation of effector caspases-3, -6 and -7 varies between the 
intrinsic and extrinsic pathways (Figure 12). On the extrinsic pathway, two types of 
signalization can occur. The first type is characterized by high levels of formed DISC and, 
consequently, an increase of active caspase-8, which on the other hand, leads to the 
activation of effector caspases-3 and -7. The second type presents low levels of DISC 
and, as such, needs an additional amplification circuit that involves the caspase-8 
cleavage of BID protein to generate tBit that leads to the release of mitochondrial 
Apoptosome 
A B 
 
Caspase-9 
Procaspase-9 
intrinsic pathway 
ATP 
SMAC/ DIABLO 
V 
XIAP 
Cytochrome C 
Apaf-1 
Figure 11: Activation of the intrinsic pathway. 
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cytochrome c. Therefore, the apoptosome is formed, procaspase-9 is activated into 
caspase-9 and the effector caspases-3 and -7 activation initiates the death cascade 
(Figure 12).5 
Cytochrome C 
Apoptosome 
 
Caspase-8,-10 
Caspase-9 
Procaspase-9 
Caspase-3,-6,-7 
Procaspase-3,-6,-7 
Apaf-1 
BID 
tBID 
SMAC/ DIABLO 
Procaspase-8,-10 
 
TNF 
FADD 
intrinsic pathway extrinsic pathway 
XIAP 
V 
V 
DISC 
Figure 12: Activation of effector caspases. 
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2.1.3. Modulation of caspases activity 
 
The activity of caspases can be regulated directly, through activators or inhibitors 
that directly bond to the caspases active or allosteric sites, or indirectly by the interference 
with signaling events along the caspases cascade that promotes caspases activation.  
To date, although several compounds have proved to interfere with the caspase activity, 
most of them act on the signaling pathway involved in caspase activation. Only a limited 
group of compounds have demonstrated to directly interfere with caspases active or 
allosteric sites. Additionally, the majority of the reported compounds act as inhibitors. In 
fact, until present, only few activators of caspases have been reported. 
 
2.1.3.1. Active site-directed inhibitors of caspases 
 
The active site-directed inhibitors include peptide-derived inhibitors and non peptidic 
inhibitors with heterocyclic scaffolds. 
 
2.1.3.1.1. Peptide-derived inhibitors 
 
The development of caspases selective inhibitors was based on substrate 
specificity. Through combinatory approaches it was possible to identify the ideal substrate 
as well as different binding requirements for caspase subfamilies. Furthermore, structural 
analysis of caspase-inhibitor complexes propitiated a better understanding of the binding 
modes and the caspases subsites geometry.2 
Many of the caspase inhibitors are peptide derivatives based on the strict 
requirement for an aspartic acid residue in the P1 position of the tetrapeptide motif 
recognized in the substrate (Figure 13).11 
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Figure 13: Structure illustrating substrate/inhibitor residues (P) and protease binding sites (S). Prime and non-
prime indications distinguish respectively between the C- and N-side of the cleavage site. 
 
The most common strategy to convert substrates to pseudosubstrate inhibitors was 
based on the Asp ligation at P1 from the peptide sequence to an electrophilic moiety, such 
as an aldehyde or fluoromethylketone. This moiety covalently interacts with the 
nucleophilic Cys of the active site and, therefore, inhibits caspases.2 
Nevertheless, the presence of the electrophilic moiety is not the only structural 
requirement to activity inhibition.2 In fact, Le et al. (2006) investigated the replacement of 
the conventional electrophilic moiety by a much less reactive azidomethylene substituent 
in a series of azidomethylene-based peptidomimetics, obtaining some potent inhibitors of 
caspase-1 (Table 1).12 
 
Table 1: Azidomethylene-based peptidomimetics inhibitors of caspase-1.12 
 
Compound IC50(nM) Mr 
3 Ac-Try-Ala-Asp-H 2±0.4 492 
4 
 
 
226±32 519 
5 
 
75±10 487 
6 
 
40±5 498 
7 
 
4.6±0.5 468 
8 
 
7.9±0.75 496 
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More recently, Loser et al13 (2010) reported some non-covalent caspase-1 peptide-
derived inhibitors based on the 2-naphthoyl-Val-Ala-Asp sequence. These inhibitors were 
produced by incorporating a secondary amine (reduced amide) isostere in place of the 
conventional electrophile (e.g., aldehyde). They showed to be potent, reversible and 
competitive inhibitors being selective for caspase-1 (e.g., Ki= 47 nM) over caspases-3 and 
-8, with minimal cytotoxicity (Table 2). Unlike most cysteine protease inhibitors, these 
compounds do not react covalently and indiscriminately with thiols.13 
 
Table 2: Benzylamine inhibitors of caspases-1.13 
 
Compound R R´ X Ki (nM) 
9 
 
H N 600±47 
10 
 
H N 47±7 
11 
 
H N 965±76 
12 
 
H N 209±21 
13 
 
H N 945±99 
14 
 
Me N 128±14 
Ki= values of inhibition constant 
 
Docking studies of the most potent compound of this series into the active site of 
caspase-1 revealed the orientation of benzylamino residue into the S1’ pocket and 
additional hydrogen interactions of the hydroxyl group in the ortho position.13 
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Several peptidomimetic caspase inhibitors were developed by pharmaceutical 
companies and have entered in clinical trials.2 One example is the broad-spectrum 
caspase inhibitor IDN-6556 (15, Figure 14) that is a potent and irreversible inhibitor of 
Fas-induced apoptosis in vitro.14 IDN-6556 (15) entered in clinical trials for treatment of 
liver diseases and in patients undergoing liver transplantation.14  
 
 
Figure 14 Structure of the active-site inhibitor IDN-6556 (15). 
 
In addition to IDN-6556, other inhibitor VX-765 (16, Figure 15) entered in clinical 
trials. VX-765 is a second generation reversible peptide-derived inhibitor that has been 
examined in clinical trials for inflammatory diseases.15 It is a prodrug that requires 
esterase cleavage of the 5-ethoxydihydrofuran-2(3H)-one moiety to yield the aldehyde 
functionality of the drug VRT-043198 (17, Figure 15). This moiety covalently interacts with 
the nucleophilic Cys of the active site and, therefore, inhibits caspases.16 
 
 
 
Figure 15: Structure of peptide-derived caspase inhibitors VX-765 (16) and VRT-043198 (17). 
 
The syntheses of several cyanopropanate-containing small molecules based on the 
peptidic scaffold of prodrug VX-765 were also accomplished (Figure 16). These 
Esterases 
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compounds were found to be selective and potent inhibitors of caspase-1 (IC50 values ≤1 
nM).15 
 
 
Figure 16: Structure of cyanopropanate-containing small molecules based on peptidic scaffold of VX-765 as 
inhibitors of caspase-1 (NCGC00185682 (18), NCGC00183434 (19) and NCGC00183681 (20)). 
 
2.1.3.1.2. Natural caspase inhibitors 
 
The first natural caspase inhibitor found was a cytokine response modifier (CrmA), a 
product of cowpox virus.  It was responsible for the effective inhibition of the interleukin-1β 
activation in chorioallantoic membranes of chicken embryos. The inhibitor interacts with 
caspase-1 active site, due to the pseudosubstrate Leu – Val – Ala – Asp sequence.17 
 
2.1.3.1.3. Nonpeptidic inhibitors 
 
Simultaneously to the development of peptidomimetic caspase inhibitors, other 
scaffolds were identified through high-throughput screening (HTS) of chemical libraries. 5-
Nitroisatin (21, Figure 17) was first discovered as a nonpeptide caspase-3 inhibitor by 
using a HTS of the Smith Kline Beechan compound collection.18 The modification of this 
compound led to the development of a series of potent isatin analog inhibitors of 
caspases-3, -7, including compounds 22 and 23 (Figure 17).19 These isatin sulfonamide 
compounds showed to be potent and selective caspase inhibitors.19 However, their use 
may be limited because of the highly reactive nature of their ketone carbonyl groups 
toward nucleophiles. So, a new class of isatin sulfonamide analog compounds has been 
achieved called isatin Michael acceptors (IMAs), like compound 24. This class has 
comparable potency against caspases-3 and -7, but reduced selectivity over caspases-1, 
-6 and -8.20 However, when pyrrolidine was substituted for a thiomorpholinyl residue 
(compound 25), an increased caspase-6 inhibition and moderate selectivity over 
Esterases 
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caspases-3 and -7 was observed, representing a new class of small molecules caspase-6 
inhibitors which could serve as lead compounds for the development of a second 
generation inhibitors.21  
 
 
Figure 17: Structures of the isatin sulfonamides caspase inhibitors 21-25. 
 
Another class of caspase inhibitors includes those possessing a 1,4 – benzodioxane 
scaffold, like compounds 26 and 27 (Figure 18). Compound BI-7E7 (26) was identified as 
an inhibitor of caspase-8-mediated peptide cleavage. Optimization of the thiazole ring 
through docking studies resulted in compound BI-9B12 (27) with an improved inhibitory 
activity on caspases-3, -7 and -8.22 
 
 
Figure 18: Structures of 1,4- benzodioxane derivatives 26 and 27. 
 
In 2005, other class of caspase inhibitors was introduced based on the 2,3-dihydro-
1H-pyrrolo[3,4-c]quinoline-1,3-dione scaffold (28, Figure 19).23 The mechanism of 
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caspase inhibition of these compounds is mediated by the nucleophilic attack of catalytic 
cysteine to one of the carbonyl functions at the fused pyrrol ring, leading to the reversible 
covalent inhibition of the targeted caspases.2 Many compounds were described based in 
this scaffold, differing at the substituents R1, R2, and R3. According to Kravchenko et al. 
(2005), caspase-3 inhibitory activity was highly dependent on substitutions on the core 
scaffold, especially at the 8-position. The compound 29 (Figure 19) with a 
morpholinesulfonyl moiety at the 8-position and a 1,3,5-trimethyl-1-H-pyrazol-4-yl group at 
the 2-position was the most potent (IC50 = 4 nM).24 
 
 
Figure 19: Caspase inhibitors with a pyrrolo[3,4-c]quinoline-1,3-dione scaffold (28) and selected caspases-3 
inhibitor (29). 
 
2.1.3.2. Allosteric inhibitors of caspases 
 
Allostery is a basic principle of control of enzymatic activities based on the 
interaction of a protein or a small molecule with a site of an enzyme distinct from the 
active one. Allosteric modulators represent an alternative approach to the design and 
synthesis of small molecule activators or inhibitors of proteases and are therefore of wide 
interest for Medicinal Chemistry.25 
Allosteric regulation involves the understanding of some concepts. The concept of 
conformational selection proposes that a protein exists in equilibrium of multiple 
conformations, some of them catalytically active, with others being inactive. With the bond 
of a preferential molecule, there is conformation stabilization (Figure 20). The 
conformational selection can arise in two ways: or a molecule bonds to the recognized 
orthosteric site through an endogenous ligand or it bonds to an allosteric site.2 
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 (Adapted) 25. 
 
Many new allosteric interactions with caspases were revealed by disulfide trapping. 
A disulfide reversible ligation is formed between cysteine residues at the target protein 
surface with a small molecule containing sulfhydryl. If a small molecule shows affinity to 
the protein, the dissulfite is stabilized and a possible modulation of the biological function 
is measured (Figure 21).26 
 (Adapted) 27 
 
 
On-state Off-state 
Substrate 
Allosteric inhibitor Active site 
Allosteric site 
Substrate 
Allosteric inhibitor 
SH 
S   S 
Off-state 
HS 
On-state 
HS 
Figure 20: Model of allosteric inhibition. A dynamic protein exists in equilibrium of several low-energy 
conformations, which are active (on-state) or inactive (off-state). Reversible binding to or irreversible 
trapping of a distinct conformation shifts this equilibrium, inducing an alteration of enzyme activity. 
 
Figure 21: Model of disulfide trapping. A dynamic protein exists in equilibrium of several low-energy 
conformations, which are active (on-state) or inactive (off-state). Protein has cysteine residues near the 
allosteric site that interact with small molecule that also contain cysteine residue, preventing the binding of 
substrate. The caspases is shown as monomer, for simplicity. 
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The first successful utilization of disulfide trapping for the caspases allosteric 
modulation was reported in 2004.28 The screening of a thiol-containing compound 
database for caspase-3 binding resulted in the discovery of DICA (30, Figure 22) and 
FICA (31, Figure 22) as new inhibitors of caspase-3. DICA and FICA were found to trap 
the enzyme in a zymogen-like conformation 29, binding selectively to Cys264 located in a 
central cavity at the dimerization interface.25 
In the caspase-7, different binding modes of DICA and FICA in the allosteric site 
were demonstrated, but an identical conformational rearrangement in the protease 
domain was observed. Both compounds induce a switch of active dimerized caspase-7 
conformation into a procaspase-7-like conformation by irreversibly trapping the zymogen-
like conformation.25 
 
 
Figure 22: Structures of the allosteric inhibitors of caspases-3 and -7 DICA (30) and FICA (31). 
  
The disulfide trapping approach was also applied to the discovery of new 
inflammatory caspase-1 inhibitors. Despite the low rate of homology between caspases-
3/7 and caspase-1, small molecule inhibitors could be identified which interfere with a 
comparable located Cys331 residue at the dimerization interface. Using this approach, 
compound 32 (Figure 23) was identified as an inhibitor of caspase-1.27 The identification 
of functional allosteric sites in C1, C3 and C7 served as source of inspiration for further 
efforts to identify allosteric modulators of these and other caspases.29  
 
Figure 23: Structure of the caspase-1 allosteric inhibitor, compound 32. 
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In addition to the small molecule allosteric inhibitors of caspases, some 
macromolecular inhibitors are also known. For example, AR-F8 is one of the caspase-2 
specific macromolecular ligands that significantly inhibits its activity. For this peptidic 
inhibitor, a high selectivity for caspase-2 over caspases-3, -7, -8, and -9 was observed. 
Contrary to compounds 30 and 31, which caspase inhibition lead to zymogen-like 
structures, AR-F8 induced only minor conformational changes within caspase-2. The 
strong inhibitory effect is due to a slight misalignment of the active cysteine site and the 
disruption of hydrogen-bond interactions between the substrate and the active site.2 
Another example of macromolecular inhibitors is the endogenous inhibitor XIAP, a 
member of inhibitor apoptosis proteins (IAPs). IAPs are a cell protein family that includes 
eight members, being six of them identified in humans. This, in general, are expressed at 
high levels in the majority of human cancers.30 XIAP protein is a caspase inhibitor of 
caspases-3, -7 and -9 that can interact not only with the allosteric site, but also with the 
active binding site, depending on the caspase. Caspase-3 and -7 are inhibited by 
prevention of substrate access to the active site whereas caspase-9 is inhibited 
allosterically.25 XIAP is composed by three baculoviral IAP repeats (BIR) with distinct 
binding properties. For caspases-3 and -7, the second BIR domain is the responsible for 
preventing the substrate bonding. On the other hand, the third BIR domain is responsible 
for XIAP-mediated inhibition of caspase-9. BIR3 bonds to the N-terminal region of the 
small subunit of caspase-9.2,5 IAPs do not bind nor inhibit caspase-8 (extrinsic pathway), 
however they bind and inhibit procaspase-3 substrate, stopping the cascade and 
protecting the caspase-8 induced apoptosis. The interaction between XIAP and caspases 
can be disrupted by several small molecules. One example is the compound 33 (Figure 
24) that interferes with XIAP’s ability to inhibit caspase-3 31, and compound 34 (Figure 24) 
that interacts with de BIR3 domain of XIAP, avoiding its bond to caspase-9.32 With this 
approach, the inhibitory effect of XIAP on caspases activity will be blocked and caspases 
activity will no longer be inhibited.  
 
 
Figure 24: Structures of XIAP inhibitors, compounds 33 e 34. 
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2.1.3.3. Small molecule activators of caspases 
 
Activation, instead of inhibition, of caspase activity with synthetic small molecules 
has been less investigated. Such small molecules can reveal key aspects in the activation 
of these enzymes and provide a direct effect on important physiological processes. Only 
in 2006, it was published the first report about caspase activators, when approximately 
20,500 structurally diverse small molecules were screened for their ability to activate 
procaspase-3 in vitro.33 The evaluation of the ability of a group of structural diverse small-
molecules to activate procaspase-3 resulted in the identification of the procaspase-3 
activator compound, PAC-1 (35, Figure 25). 
Additionally, further PAC-1 derivatives were synthesized and evaluated in order to 
determine their effects on procaspase-3. Consequently, a PAC-1 analogue (PAC-1B or 
de-allyl PAC-1, 36) was identified, with similar potency than PAC-1 (EC50 value 0.43 µM, 
PAC-1B value 0.22 µM).33 
 
 
Figure 25: Structures of PAC-1 (35) and its close analog PAC-1B (36). 
 
 
SAR studies allowed concluding that the presence of the N-benzylpiperazinyl group 
and the aromatic hydroxyl moieties are crucial for activation and the allyl group is 
dispensable for the biological activity.34 Peterson et al. (2009), demonstrated that zinc 
inhibits the enzymatic activity of procaspase-3 and that PAC-1 strongly activates 
procaspase-3 in buffers that contain zinc 34. In fact, it was demonstrated that PAC-1 and 
zinc form a tight complex with one another, with a dissociation constant of approximately 
42 nM.34 Moreover, the presence of the N-benzylpiperazinyl group and the aromatic 
hydroxyl moieties in PAC-1 seems to be fundamental for the ability of PAC-1 to bind zinc 
ions from the active site, allowing the proenzyme to autoactivate itself to caspase-3 
(Figure 26).35 Although, PAC-1 was the first compound to be considered as direct 
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activator of caspases, its direct activating ability was questioned, particularly by Denault et 
al, who demonstrated that PAC-1 and related compounds were not activating executioner 
caspases directly, reinforcing the idea that the mechanism of action is due to the zinc 
chelatio9n.36  
 (Adapted) 34 
 
The relatively short in vivo half-live of PAC-1 (2.1 ± 0.3 h in dogs)37 following i.v. 
administration is a major challenge for using this compound in vivo studies. In this sense, 
very recently, Roth et al. (2015) designed a series of PAC-1 analogues containing 
modifications that systematically block sites of metabolic vulnerability. Evaluation of the 
library of compounds identified four potentially superior candidates (37-40, Figure 27) with 
comparable anticancer activity in cell culture, enhanced metabolic stability in liver 
microsomes, and improved tolerability in mice.37 
PAC-1 
Procaspase-3 Procaspase-3 
Zn2+ 
Zn2+ 
PAC-1 
Procaspase-3 
Caspase-3 
Zn2+ 
Figure 26: The proposed mechanism for PAC-1-induced activation of procaspase-3 in vitro. In the presence of 
PAC-1, the zinc ion is removed by giving up the caspase-3 activation to function as an enzyme and 
proteolytically cleave another molecule of procaspase-3. When the zinc ion is not removed, there is an 
impediment to activation of procaspase-3. 
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Figure 27: Derivatives of PAC-1 (37, 38, 39 and 40) with enhanced metabolic stability in liver microsomes, 
and improved tolerability in mice. 
 
In 2014, several benzothiazole derivatives emerged as procaspase-3 activators, 
from a series of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone 
moiety.37,38 Among those compounds, benzothiazoles 41-43 (Figure 28) revealed to be 
potent inhibitors of human tumor cell lines and more potent than PAC-1 as procaspase-3 
activators. SAR studies demonstrated that the phenyl group on the 2-hydroxyphenyl ring 
was critical for the in vitro pharmacological activity.39 and that the introduction of a 
lipophilic group at the 4-position of the 2-hydroxy phenyl ring was beneficial to the 
antitumor activity.38 
 
Figure 28: Structures of PAC-1 analogues (41, 42 and 43). 
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In 2009, a library of approximately 62,000 compounds was tested and several hit 
compounds revealed the ability to activate procaspase-3.40 Among these, compound 1541 
(44, Figure 29) was the most potent direct activator of procaspases-3 and -6, but no 
activity was detected for procaspases-1 and -7. In addition, several 1541 analogs were 
synthesized and tested.40 Compound 1541B (45, Figure 29), possessing a 8-methoxy 
group instead of a hydroxyl group on the coumarin nucleus, showed a potent activation of 
procaspase-3, but no activity toward procaspase-6 was detected. Compound 1541C (46, 
Figure 29) with an additional bromine atom at position 6 revealed a reduced potency for 
procaspase-3, but an increased potency for procaspase-6. Furthermore, the deletion of 
the imidazopyridine metha substituent on the phenyl ring (1541D, 47, Figure 29) was 
associated with the absence of activation of procaspases-3 and -6, suggesting that the 
presence of this group was crucial for the activity.40 
 
 
Figure 29: Structures of 1541 (44) and its derivatives1541B (45), 1541C (46) and 1541D (47). 
 
Wolan et al. (2009) demonstrated that compound 44, at low concentrations, 
activates the procaspase-3 (EC50 = 2.4 µM), but at higher concentrations partially inhibits 
the active enzyme. It was proposed that compound 1541 binds near one active site of the 
dimeric procaspase and induces the formation of an active conformation, resulting in the 
subsequent enhancement of the proteolysis at the other active site. Nevertheless, at 
higher concentrations, compound 1541 binds to both active sites, causing the partial 
inhibition (Figure 30).2  
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Figure 30: The proposed mechanism of activation-assisted procaspase-3 self-activation. The activator 
inducing initial slow autoproteolytic activation phase (grey arrows). Thus, increases active caspases, resulting 
in the subsequent enhancement of the proteolysis at the other active site. 
 
 
2.2. Flavonoids 
 
The flavonoids are a group of secondary metabolites that exist either as free 
aglycones or glycosidic conjugates. They are widely found in normal human diet.41,42, 
being components of fruit, vegetables, nuts, and plant-derived drinks.43 To date, some 
10,000 different flavonoids have been characterized.44 
 
2.2.1 Chemistry 
 
Chemically, flavonoids possess a fifteen-carbon skeleton consisting of two benzene 
rings (rings A and B) that are linked by a three carbon unity which may or may not form a 
third ring (ring C). This basic structure occurs in a variety of structural forms including 
those that could be considered as structurally derivatives of 1,1-, 1,2- and 1,3-
diphenylpropane (Figure 31). The first group is known as neoflavonoids, while the second 
group is known as isoflavonoids and the third is commonly known as flavonoids 45 
Prodomain 
removal 
Intra-
domain 
cleavage 
Active site 
Allosteric site 
Activator 
Prodomain 
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Figure 31: Basic skeletons and numbering pattern of structural derivatives of 1,1-, 1,2- and 1,3-
diphenylpropane (47, 49 and 51 respectively). 
 
Considering flavonoids group, they can be subdivided into several sub-classes 
according to the presence (or absence) of a third ring, a double bond between carbon 
atoms 2 and 3, a carbonyl group on C-4, and hydroxyl groups in the C ring (Figure 32).   
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Figure 32: Basic skeletons of several subclasses of flavonoids and numbering of skeletons 
 
All flavonoids are derived from the general phenylpropanoid pathway, one of the 
best-known pathways in plant secondary metabolism.46 The first three steps of this 
pathway (Figure 33, A) involve the deamination of phenylalamin to cinnamic acid by 
phenylalanine ammonia lyase (PAL), the oxidation of cinnamic acid to 4-coumaric acid by 
cinnamate 4-hydroxylase (C4H) and the formation of 4-coumaroyl-CoA by 4-coumaroyl 
CoA ligase (4CL). Chalcone is obtained by the condensation of three molecules of 
malonyl-CoA (Figure 33, B) and one molecule of 4-coumaroyl-CoA by chalcone synthase 
(CHS) 46. The subsequent ring closure catalyzed by chalcone isomerase (CHI) produces 
flavanones which in turn serve as precursor for a large number of different flavonoids 
(Figure 33, C). From flavanones the pathway diverges into several side branches, each 
resulting in a different class of flavonoids. Flavanones can be hydroxylated by flavanone 
3β-hydroxylase (FHT) to form a dihydroflavonol, which can subsequently be reduced to 
leucoanthocyanidin, thereby initiating the synthesis of anthocyanin directed by 
α 
β 
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dihydroflanonol-4-reductase (DFR) and anthocyanidin synthase (ANS). On the other 
hand, dihydroflavonol can be directly oxidated by Flavonol synthase (FLS) forming 
flavonols.44 
 
 
Figure 33: Biosynthesis of flavonoids. PAL: Phenylalanine ammonia-lyase, C4H: Cinnamic acid 4-
hydroxylase, 4CL: 4-Coumarate:Coenzyme A ligase, CHS: Chalcone synthase, CHI: Chalcone isomerase, 
FHT: Flavanone 3β-hydroxylase, FNS Ι: Flavone synthase Ι, FLS: Flavonols synthase, DFR: Dihydroflavonols 
reductase, ANS: Anthocyanidin synthase. 
(Adapted). 44 
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2.2.1. Biological activities 
 
The diversity of structural patterns has resulted in flavonoids being recognized as a 
rich source of compounds with diverse biological activities47, namely antioxidant 42,48, 
antimutagenic 49, antibacterial 50, antiangiogenic 51,52, anti-inflammatory 53,54, antiallergic 55, 
and anti-tumor activity 43,56,57. In addition, these natural products have also been described 
for their ability to modulate the acivity of several enzymes (lipoxygenase,58,59 Cytochrome 
P450 monooxygenases,60 protein kinase C,60,61 topoisomesare I,62 tyrosinase,63,64 
aromatase65) as well as to modify the behaviour of many cell systems (functions of 
inflammatory cells, smooth muscle and cardiac muscle cells, effects on nerve cells).66 
 
2.2.1.1. Flavonoids as antitumor agents 
 
Among the activities reported for flavonoids, the antitumor activity is one of the most 
exhaustively studied.  The ability of flavonoids to arrest the cell cycle, induce apoptosis, 
disrupt mitotic spindle formation, and inhibit angiogenesis makes them promising agents 
in anticancer research.51 
Natural flavonoids and their synthetic analogs have been intensely studied in the 
treatment of ovarian, breast, cervical, pancreatic, and prostate cancers.51 The interesting 
anticancer properties of flavonoids in preclinical studies have encouraged their entrance in 
clinical trials. In fact, the natural flavonoid genistein (54, Figure 34) and the semi-synthetic 
flavone flavopiridol (55, Figure 34) have entered clinical trials for several cancers.51 
Genistein (G-2535), a soy derived isoflavone, was found to be a potent agent in 
prevention and treatment of cancer.67 Flavopiridol (NCS 649890) is derived from the 
indigenous Indian plant Dysoxylum binectariferum, and it was the first CDK inhibitor to be 
tested in clinical trials.68,69 
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Figure 34: Examples of natural flavonoids that have entered in the late phase of clinical trials for various 
cancers. 
 
Given the importance of the antitumor activity of flavonoids, several studies have 
been conducted in order to get some insights into the cellular and molecular mechanisms 
of action of these compounds. Flavonoids display a vast array of cellular effects, affecting 
the overall process of carcinogenesis in different stages (initiation, promotion and 
progression) by several mechanisms (Figure 35)47, including inhibition of DNA 
topoisomeraseI/II activity70,71, regulation of reactive oxygen species72, cell cycle arrest57, 
modulation of proliferation pathways73, and interference with the apoptotic cascade.74,75 
 
Figure 35: Multistage model of carcinogenesis and potential effects of flavonoids on cancer progression. 
Red arrows indicate the inhibited systems and the green arrows indicate the activated systems by 
flavonoids. 
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Additionally, flavonoids have been reported to modulate several protein kinases. 
Protein-kinases (PKs) are enzymes that catalyse the phosphorylation of different cellular 
substrates. Deregulation of PKs can lead to alterations in phosphorylation that result in 
several abnormalities, namely in uncontrolled cell division and inhibition of apoptosis, 
being these effects closely linked to various cancers.76 So, inhibition of PKs is an 
important aspect in cancer chemoprevention by the flavonoids. Some examples of the 
protein kinases that are inhibited by flavonoids include serine/threonine kinases, 
phosphatidylinositol kinase and cyclin-dependent kinases.51 
Flavonoids are also capable of interact with several receptors which play important 
roles in cancer pathology 77, namely the epidermal growth factor receptors (EGFRs)78-80, 
platelet derived growth factor receptors (PDGFRs), vascular endothelial growth factor 
receptors (VEGFRs)81,82 and cyclin-dependent kinases (CDKs).83 
 
2.2.1.2. Flavonoids as pro-apoptotic agents in cancer 
 
Activation of apoptosis is a key molecular mechanism responsible for the anticancer 
activities of several currently studied potential anticancer agents, including flavonoids.84 
Several reports indicate that these compounds may induce apoptosis by affecting the 
expression or activity of a wide range of molecules involved in apoptosis pathways 
(Figure 36). In fact, the induction of apoptosis by flavonoids can be related to the 
activation of caspases, decrease of variation of the membrane potential (∆Ψm), release of 
cytochrome c from mitochondria, regulation of Bcl-2 family proteins members, and 
regulation of IAP by release of Smac/DIABLO from mitochondria, cleavage of poly (ADP-
ribose) polymerase (PARP), increase levels of reactive oxygen species (ROS) and 
activation of death receptors (Figure 36). 
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Figure 36: Flavonoids may induce apoptosis by affecting the expression or activity of a wide range of 
molecules involved in apoptosis pathways. 
Chapter 2: Introduction 
 
41 
Some examples of flavonoids that induce apoptosis by modulating different key 
targets involved in apoptotic pathways, including caspase family proteins are listed in 
Table 3. Despite few structure-activity relatioship studies (SAR) have been conducted 
regarding antitumor activity of flavonoids, some researchers suggest that flavones and 
flavonols are the most potent flavonoids.85 So, the flavonoids listed in Table 3 are 
restricted to these two classes of flavonoids.  
 
Table 3: Some flavones and flavonols reported since 2000 as inducers of apoptosis by modulating different 
key targets involved in apoptotic pathways, including caspase family proteins reported. 
 
Compound Target or affected process References 
Natural flavones and flavonols 
Methoxyflavones and flavonols 
 
56: nobiletin 
 
-Decrease Bcl-2 expression 
-Increase Bax expression 
-Increase caspase-3 expression, 
in HCC cell line SMMC-7721 
and  HCC cell line H22 
-Induction of cell cycle arrest in 
G0/G1 phase 
-Inhibition ERK 
-Activation of p38 
-Activation of caspase-8,-9 and -
3, in HL-60 AML cells 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
HUVEC 
-Cleavage of PARP 
-Decrease Bcl-2 expression 
-Increase p21 expression 
-Increase caspase-3,-7 and -9 
activities 
86-89 
 
57:5-Hydroxy-3,6,7,8,3',4'-
hexamethoxyflavone (5-OH-HxMF) 
 
 
-Decrease ∆Ψm 
-Increase levels of ROS 
-Increase caspase-2, -3, -6 and 
-7 activities 
-Cleavage of PARP 
-Increase Bad expression, in 
HL-60 cells 
90 
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58: R=OCH3, tangeretin 
59: R=OH, 5-DT 
 
-Decrease ∆Ψm 
-Increase caspases-3, -8 and -9 
activities 
-Increase Bax expression 
-Increase Bid expression 
-Increase tBid expression 
-Increase Fas expression 
-Increase FasL expression 
-Increase p53 expression, in 
AGS cells 
-Arrest cell cycle in G2/M phase 
-Increase caspases-3, -7 and -9 
activities 
-Decrease Mcl-1 expression 
-Decrease Bcl-Xl expression, in 
K562 cells 
-Increase p53 expression 
-Increase Bax expression 
-Decrease cdc-2 (cdk1) and 
cyclin B1 expression 
-Increase p21 expression 
-Cleavage of PARP, in human 
nonsmall cell lung cancer 
(H460,H1299 and A549) cells 
91-93 
 
 
 
 
60: R3,R4´,R5´=H; R5,R7=OCH3,DMF 
61: R3,R5´=H; R5,R7,R4´=OCH3, TMF 
62: R3,R5,R7,R5´,R4´=OCH3, PMF 
63: R3,R7,R2´R4´,R5´=H; R5=OCH3, 
5-MF 
64: R3,R5,R7,R4´,R5´=H R2´=OCH3, 
2´-MF 
 
-Increase DRs expression 
-Decrease cFLIP expression 
-Decrease Mcl-1 expression 
-Increase Bax expression 
-Decrease Bid expression 
-Activation of caspase-3 and -8 
-Increase oxidative stress, in 
human leukemic MOLT-4 cells 
5-MF: 
-Increase caspases-3 and -7 
activation 
-Cleavage of PARP 
,in HCT116 colo cancer cells 
94,95 
   Hydroxyflavones and flavonols 
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65: luteolin 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Cleavage of PARP 
-Increase Bad expression 
-Increase Bax expression 
-Decrease Bcl-2 expression 
-Decrease Bcl-Xl expression 
-Induce and increase caspase-3 
and -9 activities, in HL-60 cells 
-Inhibit Bcl-2 expression 
-Increase Bax expression 
-Increase caspase-3 activity, in 
MG-63 cells 
-increased Fas expression 
-Activation of caspases-8 and -
3, in MDA-MB-231 
 
96-98 
 
 
66: apigenin 
 
-Increase levels of ROS 
-Induction of cell cycle arrest in 
G2/M phase, in SCC25 and 
A431 cells 
-Increase TNF-R expression 
-Increase TRAIL-R expression 
-Decrease Bcl-2 expression 
-Activation of caspase-3, in 
SCC25 cells 
-Increase levels of ROS 
-Decrease ∆Ψm 
-Increase cit c release 
-Increase Bax expression 
-Decrease Bcl-2 expression 
-Activation caspases-3 and -9, 
in A375 and A549 cells 
-Increase cit c release 
-Increase caspase-3 activity, in 
breast cancer cells (with 
HER2/neu-over-expressing) 
-Increase caspase-3 and -9 
activities 
-Increase levels of ROS 
-Activation of ERK and p38, in 
THP-1 cells 
-Increase caspase-3 activity 
-Cleavage of PARP 
-Increase Bax expression, in 
NUB-7 cells 
99-103 
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-Increase levels of ROS 
-Decrease ∆Ψm 
-Increase cit c release 
-Increase Bax expression 
-Decrease Bcl-2 expression 
-Decrease Bcl-xl expression 
-Cleavage of PARP 
-Increase caspse-3 and -9 
activities, in 22Rv1 cells 
 
 
67: 7,8-DHF 
 
-Increase Fas expression 
-Increase FasL expression 
-Increase DR4 expression 
-Increase TRAIL expression 
-Activate caspase-3,-8 and -9 
-Cleavage of PARP 
-Increase Bax expression 
-Increase cit c release 
-Activation ERK and JNK, in 
U937 cells 
 
104 
 
68: morin 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Decrease Bcl-2 expression 
-Increase Bax expression 
-Cleavage of PARP 
-Increase caspase-3, -8 and -9 
activities, in U937 cells 
105
 
 
69: kaempferol 
 
-Decrease Bcl-xL expression 
-Increase p53 expresson 
-Increase Bad expression 
-Increase Bax expression 
-increase caspase-3 and -7 
activities, in Ovarian cancer cell 
lines (OVCAR-3, A2780/CP70, 
and A2780/wt), 
- Decrease Bcl-xL expression 
-Increase Bad expression 
-Cleavage of PARP 
-Increase caspase-3, -7, -8 and 
-9 activity in HT-29 Human 
Colon Cancer Cells 
-decrease Bcl-2 expression 
-Increase Bax expression 
106-108 
Chapter 2: Introduction 
 
45 
-Cleavage of PARP 
-increase caspase-3 and -9 
activities, in  gastric cancer 
 
 
70: quercetin 
 
-Decrease ∆Ψm 
-Increase Bax expression 
-Decrease Bad expression 
-increase caspase-3,-8 and -9 
activities, in MDA-MB-231 cells 
-Decrease Bcl-xL expression 
-Increase Bax expression 
-Increase caspase-3 and -9 
activities, in HepG2 cells 
109,110 
   Methoxy- and-Hydroxyflavones and Flavonols 
 
 
71: R1 =OCH3; R2,R3,R4,R5= H, 
wogonin 
72: R1, R2= H; R3,R4,R5=OH, fisetin 
73: R1=OH; R2,R3,R4,R5=H, nor-
wogonin 
 
wogonin : 
-Increase levels of ROS 
-Decrease ∆Ψm 
-Increase caspases-3,-9 and -8 
activities 
-Increase Bax expression 
-Increase Bad expression 
-Increase cit c release 
-Increase Fas/CD95 ,In U-2 OS 
-increase TRAIL-R2 expression, 
in ATL cells 
-Increase levels of ROS 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
HL-60 cells 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
SK-HEP-1 cells 
nor- wogonin: 
-Increase levels of ROS 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
HL-60 cells 
Fisetin: 
Cleavage of PARP 
-Increase caspase-3 activity, in 
SK-HEP-1 cells 
111-114 
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74: acacetin 
 
-Induce caspases-3,-8 and -9 
activities 
-Increase FADD expression 
-Increase FAF1 expression 
-Increase Apaf-1 expression 
-Increase cit c expression 
-Increase Bax expression 
-Decrease Bcl-2 expression, in 
human  T cell leukemia Jurkat 
cells 
-Decrease Bcl-2 expression 
-Decrease ∆Ψm 
-Increase levels of ROS 
-Activation of the SAPK/JNK1/2 
and c-JUN 
-Activation of caspase-7 and -8, 
in MCF-7 cells 
-Cleavage of PARP 
-Decrease ∆Ψm 
-Increase levels of ROS 
-Increase cit c release 
-Increase Bax expression 
-Increase p53 expression 
-Increase Fas expression 
-Increase Bad expression 
-Decrease Bcl-2 expression 
-Increase caspase-3 activity, in 
AGS cells 
115 116,117 
 
75: eupatilin 
 
-Decrese Bcl-2 expression 
-Increase Bax expression 
-Cleavage of PARP 
-Cleavage of caspase-3 
-Decrease ∆Ψm , in AGS cells 
118 
 
76: Skullcapflavone I 
 
-Cleavage of PARP 
-Increase caspases-3 and -9 
activities, in T-HSC/Cl-6 cells 
 
119 
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77: jaceosidin 
 
-Increase levels of ROS 
-Cleavage of PARP 
-Decrease Bcl-2 expression 
-Increase Bax expression 
-Increase p53 expression 
-Inhibition of the ERK pathway, 
in MCF10A-ras cells 
120 
 
78: cirsilineol 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Cleavage of PARP 
-Increase caspase-3 and -9 
activities, in CAov-3 cells 
 
121 
 
79:R1=H,R2=OMe,R3=OMe, 5HPMF 
80: R1,R2,R3=OMe, 5HHMF 
81: R1=H,R2=H,R3=OMe, 5HTMF 
-5HPMF  induces cell cycle 
arrest in G2/M in HCT116 and 
HT29 cells 
-Cell cycle arrest in G0/G1 
phase 
-Decrease Mcl-1 expression 
-Cleavage of PARP 
-Decrease iNOS expression 
-Decrease COX-2 expression, in 
H1299 cells 
-5HTMF  induces cell cycle 
arrest in G0/G1 phase 
-Decrease Mcl-1 level, in 
HCT116, HT29 and H1299 cells 
-Decrease Mcl-1 expression 
-Cleavage of PARP 
-Decrease iNOS expression 
-Decrease COX-2 expression, in 
H1299 cells 
- 5HTMF induces cell cycle 
arrest in G2/M phase 
-Increase p53 expression 
-Increase Bax ecpression 
-Decrease cdc-2 (cdk1) and 
cyclin B1 expression 
-Increase p21 expression 
-Cleavage of PARP, in human 
nonsmall cell lung cancer 
(H460,H1299 and A549) cells 
-Increase Bax expression, in 
H460 and A549 cells 
122-124 
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-Increase caspases-3 activity 
-Cleavage of PARP, in H460, 
H1299 and A549 cells 
-5HHMF increase Fas 
expression 
-Increase FasL expression 
-Increase FADD expression 
-Increase TRADD expression 
-Increase DR4 expression 
-Increase caspases-3,-9 and -8 
activities 
-Cleavage of PARP ,in AGS 
cells 
 
82: eupafolin 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Activation caspases-3,-6,-7,-8 
and -9 
-Decrease Bcl-2 expression 
-Increase tBid expression, in 
HeLa cells 
 
125 
 
83:5,3'-dihydroxy-3,6,7,8,4'-
pentamethoxyflavone (DH-PMF) 
 
-Decrease XIAP expression 
-Decrease cFLIP expression 
-Decrease Mcl-1 expression 
-Decrease Bcl-2 expression 
-Decrease Bcl-Xl expression 
-Increase Bax expression 
-Processing procaspase -3, -8 
and  -9 
-Cleavage of PARP 
-Arrest cell cycle in G2/M phase 
-Increase p21 expression 
-Inhibit AKT activity, in human 
myeloid KBM-5 cells 
126 
 
84: hispidulin 
 
-Activation of MAPK 
-Decrease Mcl-1 expression 
-Cleavage of PARP, in SKOV3 
cells 
-Decrease ∆Ψm 
-Increase ROS level 
-Increase cit c release 
-Inhibit Akt activation 
-Cleavage of PARP 
-Decrease bcl-2 expression 
127,128 
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-Increase bax expression 
-Increase caspase-3 activity, in 
HepG2 cells 
 
 
85: 5,4'-dihydroxy-3,7,8-trimethoxy-
6-c-methylflavone (PD1) 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Activation of caspase-3, in HL-
60 human leukaemia cell line 
129 
Other 
 
86: flavone 
 
-Decrease NF-kB expression 
-Decrease COX-2 expression 
-Increase p21 expression 
-Increase Bak expression 
-Decrease bcl-XL expression 
-Increase caspase-3 activity, in 
HT-29 cells 
-Increase levels of ROS 
-Increase p21 expression 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
HT-29, COLO-205 and COLO-
320-HSR cells 
-Arrest cell cycle in G2/M phase 
-Decrease bcl-2 expression 
-Increase caspase-2,-3,-8,-9 
and -10 activities,  in HCT-116 
cells 
 
130-132 
 
 
87: artonin B 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Decrease Bcl-2 expression 
-Increase Bax expressiom 
-Increase Bak expression 
-Increase caspase-3 activity, in 
CCRF-CEM cells 
133 
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88: baicalin 
-Increase levels of ROS 
-Increase activities of caspases-
3,-8 and-9, in SW620 cells 
-Cleavage of PARP 
-Activation of caspases-3 and-9, 
in CA46 Burkitt lymphoma cells 
134,135 
 
89: R= CH, protoapigenone 
90: R= COH, DEDC 
 
-Decrease ∆Ψm 
-Decrease Bcl-2 expression 
-Decrease Bcl-xL expression 
-Increase levels of ROS 
-Activation of caspases-3 and -9 
-Cleavage of PARP 
,in MDA-MB-231 cells 
-Decrease Bcl-2 expression 
-Decrease Bcl-xL expression 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
SKOV3 cells 
-Arrest cell cycle in S and G2/M 
phases, in SKOV3  and MDAH-
2774 cells 
-Cleavage of PARP 
-Increase caspase-3 activity 
-Activation of ERK and JNK ½ 
-Arrest cell cycle in S and G2/M 
phases, in LNCap cells 
-Decrease ∆Ψm 
-Reduce Bcl-2 expression 
-Increase cit c release 
-Activation of caspases-3,-8 and 
-9 
-Stimulated phosphorylation of 
JNK and p38, in HepG2 cells 
 
136-139 
 
91: gancaonin 
 
-Activation of caspase-3 and -7, 
in CCRF-CEM cells 
140 
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92: 5,2´,4´-trihydroxy-6,7,5´ 
trimethoxyflavone (TTF1) 
 
-Decrease Bcl-2 expression 
-Increase Bax expression 
-Increase cit c release 
-Increase caspases-3 and -9 
expression 
,in HepG-2 cells 
141 
 
93: 7,7’’-dimethoxyagastisflavone 
 
-Increase activity of caspase-3 
-Decrease ∆Ψm, in HT-29 cells 
142 
 
94: DICO 
 
-Decrease ∆Ψm 
-Cleavage of PARP 
-Activation of caspases-3 and -9 
-Increase Bax expression 
-Decrease Blc-2 expression 
-Increase cit c release 
-Arrest cell cycle in G2/M phase, 
in HepG2 cells 
143 
Synthetic Flavones and Flavonols 
 
95: HQS-3 
 
-Increase Bax expression 
-Decrease Blc-2 expression 
-Cleavage of PARP 
-Increase levels of ROS, in 
HepG2 cells 
144 
 
 
96: LYG-202 
-Cleavage of PARP 
-Activation of caspase-3,-8,-9 
-Decrease Bcl-2 expression 
-Increase Bax expression, in  
S180 and HCT-116 cells 
-Increase TNF-α activity 
-Increase caspases-3,-9 and -8 
activities 
-Cleavage of PARP 
-Cleavage Bid, in HepG2 cells 
145-147 
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97: DHF-18 
 
-Decrease ∆Ψm 
-Increase ROS levels 
-Increase TNF-R1 
-Increase Bid,  HepG2 cells 
148 
 
98:  eupatorin 
 
-Processing and increase 
caspase-3,-6,-7 -9 and -8 
activities 
-Cleavage of PARP 
-Increase cit c release 
-Increase AIF release 
-Increase Smac/ DIABLO 
release 
-Decrease Bcl-2 expression or 
cleavage Bcl-2 
-Arrest cell cycle in G2/M phase, 
in HL-60, U937 and Molt-3 cells 
-Activation of ERK and JNK, in 
HL-60 cells 
-Increase ROS level, in HL-60 
and Molt-3 cells 
 
149 
 
99: flavopiridol 
-Increase caspase-3 and -8 
expression 
-Increase p53 expression 
-Arrest cell cycle in G0/G1 and 
G2/M phase, in CD133+high/ 
CD44+high prostate CSCs 
-Inhibits iNOS expression 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
CLL 
150,151 
 
100:V8 
 
-Increase levels of ROS 
-Decrease ∆Ψm 
-Increase cit c release 
-Decrease Bcl-2 expression 
-Increase BH-3 expression 
-Increase Bax expression 
-Processing procaspase-3 and -
9, in HepG2 cells 
152 
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101: R=(CH2)5N(CH2CH3)2 LW-214 
 
-Cleavage of PARP 
-Increase ROS level 
-Activation of ASK, in MCF-7 
cells 
153 
 
102:3,3´-diamino-4´-
methoxyflavone(DD1) 
 
-Recruitment of mitochondria 
-Increase Bax expression 
-Decrease Bad expression 
-Activation of caspases-8,-9 and 
-3 
-Cleavage of PARP, in Acute 
myeloid leukemia (monoblast 
U937) 
154 
 
103: 3,6-dihydroxyflavone 
 
-Increase ROS level 
-Cleavage of PARP 
-Decrease ∆Ψm, in leukemia 
HL-60 cells 
155 
 
104: 5,7,3’-trihydroxy-3,4’ 
dimethoxyflavone (THDF) 
 
-Arrest cell cycle in G2/M phase 
-Increase cit c release 
-Cleavage of PARP 
-Processing of  caspase-3,-6,-7 
and -9 
-Inhibition ERK and JNK, in HL-
60 and U937 cells 
156 
 
105: 5,7-dimethoxyflavone 
 
-Decrease Bcl-xL expression 
-Increase Bax expression 
-Increase caspase-3 expression, 
in HCC cells 
157 
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106: ayanin diacetate 
 
-Decrease ∆Ψm 
-Increase cit c release 
-Cleavage of PARP 
-Increase caspase-8 and -9 
activities 
-Decrease Bcl-XL expression 
-Cleavage of Bid, in leukemia 
cells 
158 
 
107: 8-bromo-7-methoxychrysin 
 
-Arrest cell cycle in G1 phase, in 
HepG2 and Bel-7402 cells 
-Increase caspase-3 activity 
-Increase ROS level, in HepG2 
cells 
 
159 
 
108:WYCO2-9 
 
-Increase levels of ROS 
-Decrease ∆Ψm 
-Activation of caspases-3 and -9 
-Cleavage of PARP 
,in DU145 prostate cancer cells 
160 
 
109: R=Cl, methyl 2-(2-
chlorophenyl)-6,7-dimethyl-4-oxo-
4H-chromene-8-carboxylate 
110: R=CH3, 1 methyl 6,7-dimethyl-
4-oxo-2-(o-tolyl)-4H-chromene-8-
carboxylate 
 
-Cleavage of PARP 
-Increase cit c realese 
-Activation of the ERK pathway, 
in HL-60 cells 
161 
 
111: 4’-bromoflavonol 
 
-Increase caspase-3,-6,-7 -9 
and -8 activities 
-Increase TRAIL expression 
-Increase DR4 expression 
-Increase DR5 expression 
-Decrease Bid expression 
-Arrest cell cycle in S phase, in 
HL-60 cells 
-Decrease Bid expression, in 
162 
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Molt-3 cells 
-Increase caspase-3,-6-7,-8 and 
-9 activities 
-Increase TRAIL expression 
-Increase DR4 expression 
-Increase DR5 expression 
-Processing of Bid 
-Arrest cell cycle in S phase, in 
U937 cells 
 
112:6-chloro-2-(3,5-
dimethoxyphenyl)-4H-chromen-4-
one 
 
-Increase caspases-8 and -9 
activities 
-Increase Bax expression 
-Decrease bcl-2 expression, in 
HepG-2 cells 
163 
 
113: 2´-Nitroflavone 
 
-Increase TRAIL expression 
-Increase DR5 expression 
-Increase Bax expression 
-Increase cit c release 
-Induction cell cycle arrest in 
G2/M phase 
-Activation of p38 and JNK, 
-Decrease ERK, in HL-60 cells 
-Increase Bax expression 
-Increase Fas expression 
-Increase caspase-3, -8 and-9 
activities 
-Increase cit c release 
-Increase Bax expression 
-Decrease Bcl-2 expression 
-Decrease Bcl-Xl expression, in 
LM3 murine mammary 
adenocarcinoma cells 
-Decrease Bcl-xl expression 
-Increase Bax expression 
-Increase Fas expression 
-Increase Fas-L expression 
-Increase cit c release 
-Increase caspase-3,-8 and -9 
activities, in HeLa human 
cervical carcinoma cells 
164-166 
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114:diethyl flavon-7-yl phosphate 
(FP) 
 
-Cleavage of PARP 
-Increase caspase-3 activity, in 
HeLa cells 
167 
 
(PARP= poly (ADP-ribose) polymerase; ASK-1=apoptosis signal regulating kinase 1; ROS= 
reactive oxygen species; cit c=cytochrome c; ∆Ψm= variation of the membrane potential; 
MARK=mitogen-activated protein kinases; ERK=extracellular-regulated kinase; JNK=c-Jun N-
terminal kinase; NF-R= tumor necrosis factor receptor; TRAIL-R=TNF-related apoptosis-inducing 
ligand receptor; Mcl-1=anti-apoptotic BCL-2 protein) 
 
As described in Table 3, most flavonoids that significantly induce apoptosis in tumor 
cells are not direct activators of caspase family proteins, but interfere with other targets 
related to the intrinsic or extrinsic apoptosis pathways and consequently, increase the 
caspases expression or levels in tumor cell lines. In fact, the reports about the direct 
activation of caspases by flavonoids are rare. Recently, in 2014 two activators of caspase-
7 (1 and 2, Figure 1, pag 4) were discovered by Pereira et al. (2014). Compounds 1 and 2 
are two prenylated derivatives of baicalein (B, Figure 37) and 3,7-dihydroxyflavone (H, 
Figure 37), two natural flavonoids that have shown to be potent inhibitors of tumor cell 
lines, being this effect attributed at least in part to an apoptotic response.168-170 Moreover, 
it was demonstrated that the introduction of prenyl side chains on baicalein (B) and 3,7-
dihydroxyflavone (H) was associated with an increase of their human tumor cell lines 
growth inhibitory activity.171 
In this work, innovative assays using Saccharomyces cerevisiae individually 
expressing human caspases-3, -7 or procaspases -3, -7 were developed for screening 
assays. The validation of this model was accomplished by testing the effect of the known 
activator of caspase-3 and -7, PAC-1 (35, pag 29).172 
For development of yeast growth-inhibition assays, initially it has been found that the 
expression of human procaspases-3 and -7 have no effect on cell growth. While the 
expression of the cleavaged caspases-3 and -7 have a marked effect on cell growth. The 
relation between this effect and the expression of these human proteins was confirmed by 
Western Blot analysis.173,174 It was also found that PAC-1 induced growth inhibition in 
Table 3(contd) 
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yeast cells expressing procaspases-3 and -7 and caspases-3 and -7. These results 
indicated that PAC-1 was able to activate these caspases, as well as their inactive 
zymogens, in this model. 
Using the same model, flavonoids 1 and 2 also induced procaspase-7-mediated 
growth inhibition and increase the caspase-7-induced growth inhibition. Nevertheless, no 
effect on yeast expressing procaspase-3 and caspase-3 were observed with these 
compounds. These results suggested that, in opposition to PAC-1, flavonoids 1 and 2 
were selective activators of caspase-7. In vitro processing assays confirmed that both 
flavonoids 1 and 2 directly processed procaspase-7 to the active caspase-7.175 
The effect of these flavonoids was also evaluated in HL-60 and MCF-7 human tumor 
cell lines. HL-60 is an acute promyelocytic leukemia cell line expressing both caspases-3 
and -7, while MCF-7 is a breast adenocarcinoma cell line that only expresses caspase-7. 
The results reveled that both flavonoids inhibit the growth of the two cell lines with a 
similar GI50, confirming an effect independent of caspase-3. 
Considering the structure of flavonoids 1 and 2, and their building blocks, as no 
activity was observed for compound 2, it was suggested that the presence of the 7-prenyl 
group of flavonoid 1 seems to be associated with selectivity of this flavonoid to caspase-7, 
and the presence of the 7-geranyl of flavonoid 2 seems to be associated with the 
caspase-7 activation. 
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3.1. Chemistry 
 
Analogues of the prenylflavonoids FP2 (1) and FP11 (2) were synthesized by 
molecular modification of three natural flavonoids: baicalein (B), 3,7-dihydroxyflavone (H) 
and chrysin (C) (Figure 37). 
 
   
              (B)                     (H)    (C) 
Figure 37: Natural flavonoids used as building blocks for molecular modification. 
 
Since baicalein (B) and 3,7-dihydroxyflavone (H) were the precursors of FP2 and 
FP11, both natural flavones were chosen as building blocks. Additionally, these natural 
compounds have already demonstrated to have antitumor activity in human tumor cell 
lines, which seems to be related to the interference with caspases-dependent 
pathways.168,176,177 Similarly, the antitumor activity of chrysin (C) has also been 
described178, as well as its capacity to induce apoptosis through caspases-dependent 
pathways84,179 and the interference with other molecules involved in the apoptotic 
cascade.180 Moreover, considering the similarity of the substitution pattern on A ring 
between, baicalein (B), 3,7-dihydroxyflavone (H), and chrysin (C), the molecular 
modification of these three building blocks and the study of their caspase modulatory 
activity will allow to study the influence of the ring-A substitution pattern, namely the 
hydroxylation pattern, on the caspase modulatory activity. 
The molecular modification follow the alkylation of the natural flavonoids using 
alkylating agents possessing 1-5 carbon atoms, including linear (methyl, ethyl, propyl, 
allyl, butyl) and branched chains (isopentyl and prenyl) with or without unsaturation, 
aiming to allow SAR Studies.  
The synthesis of the alkylated derivatives followed nucleophilic substitution reactions 
of the building blocks with alkyl halide in alkaline medium. 
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3.1.1. Synthesis 
 
3.1.1.1. Optimization of baicalein alkylation 
 
Previous studies revealed that the direct alkylation with prenyl and geranyl bromide 
of baicalein (B) gave a mixture of the mono- and dialkylated  derivatives, as well as the 
building block.171 In addition, it has been demonstrated that the 7-monoprenylated 
derivatives were potent inhibitors of human tumor cell lines, in opposite to the 6,7-
diprenylated derivatives, being this effect related, at least in part, to the activation of 
caspase-7.175 Although no antiproliferative activity have been found for these 6,7-
diprenylated derivatives, other 6,7- modified baicalein derivatives have reveal interesting 
antitumor activity.181,182 Moreover, several structure related flavones possessing a similar 
substitution pattern in A ring (hydroxyl group in C-5 and alkyloxy groups in C-6 and C-7) 
revealed to be potent inhibitors of human tumor cell lines. For example, among the 
flavones listed in Table 3 (pag 46, 50 and 51), compounds 78, 92, 95, 97 and 98 showed 
pro-apoptotic effect by modulating different key targets involved in apoptotic pathways, 
including caspase family proteins.  Therefore, the direct alkylation of this building block 
was investigated by HPLC-DAD to determine the more suitable amount of alkyl halide 
necessary to obtain mainly the monoalkylated derivative but also some amount of the 
dialkylated derivative, to be used in the biological assays. Since it would be difficult to 
perform this study for all alkylating agents, it was decided to optimize the conditions for 
the longest and branched chain without unsaturation (isopentyl iodide).  
 
3.1.1.1.1. Optimization of chromatographic conditions 
 
Baicalein mono- (Biso1) and diisopentyl- (Biso2) derivatives were synthesized as 
described in Figure 38 and after their purification and characterization by IR and NMR, 
were used as standards for the HPLC-DAD study. 
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Figure 38: Synthesis of alkylated derivatives of Baicalein (B). 
 
Firstly, the chromatographic conditions to quantify Biso1 and Biso2 as well as 
baicalein in the reaction mixture were established. To fullfil this, a mixture of these 
compounds was analized by HPLC-DAD on C18 HPLC column using several mixtures of 
MeOH:H2O:MeCO2H as mobile phase. As shown in Figure 39 the mixture 
MeOH:H2O:MeCO2H (95:5:1 v/v/v) allowed to obtain the suitable chromatographic 
conditions to quantify the major constituents of the reaction with a good resolution (Figure 
39).  
 
 
 
Figure 39: HPLC-DAD chromatogram of a mixture of baicalein (B) 5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-
4H-chromen-4-one (Biso1) and 5-hydroxy-6,7-bis(isopentyloxy)-2-phenyl-4H-chromen-4-one (Biso2) at 275 
nm with MeOH:H2O:MeCO2H (95:5:1 v/v/v) as mobile phase. 
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However, after the injection of the crude product it was found that the reaction 
mixture was extremely complex and the peaks of baicalein (B) and Biso1 were 
overleaped with the peaks of other products, being not possible to quantify baicalein (B) 
and Biso1 using this chromatographic conditions (Figure 40 A). 
 
 
Figure 40: HPLC-DAD chromatograms at 275 nm of the reaction mixture with isopentyl iodide, with (A) 
MeOH:H2O:MeCO2H (95:5:1 v/v/v) and (B) MeOH:H2O:MeCO2H (50:50:1 v/v/v) as mobile phase. 
 
Consequently, a new optimization was required for the chromatographic conditions 
to quantify baicalein (B) and Biso1. After some attempts, the mixture 
MeOH:H2O:MeCO2H (50:50:1 v/v/v) was considered the best mobile phase for these 
quantifications (Figure 40 B). Therefore, the quantification of B and Biso 1 in the reaction 
mixture was performed by isocratic elution using a mixture of MeOH:H2O:MeCO2H 
(50:50:1 v/v/v) and the quantification of Biso2 was achieved by isocratic elution using a 
mixture of MeOH:H2O:MeCO2H (95:5:1 v/v/v). 
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3.1.1.1.2. Optimization of reaction time 
 
After the optimization of chromatographic conditions, six alkylation reactions of 
baicalein with isopentyl iodide were performed by MAOS with different irradiation times, as 
described in section 5.1.1.2.2., and their reaction mixtures were analyzed by HPLC-DAD 
in order to optimize the reaction time (Table 4). 
 
Table 4: Alkylation of baicalein (B) with isopentyl iodide with different reaction times. 
 
 Reaction time baicalein (%) Biso1 (%) Biso2 (%) 
10 min 51.98 26.75 0 
20 min 22.83 21.13 0.97 
30 min 8.97 18.72 0.97 
40 min 8.88 15.83 1.41 
50 min 8.79 9.32 4.98 
60 min 8.72 5.92 0.53 
 
Comparing the results presented in Table 4 it was found that the best reaction time 
for obtaining Biso1 was 10 min. However, Biso2 were not detected by HPLC and only 
half of the starting material was consumed. For reaction times longer than 20 minutes, 
although more starting material was consumed, a decreased of the amount of Biso1 and 
an increase of Biso2 was detected. This results suggested that Biso1 was converted into 
Biso2. When using a reaction time of 60 minutes the Biso1 and Biso2 yields decreases 
drastically, even though the amount of baicalein remains the same, being observed the 
formation of several undesirable by-products. Thus, it was concluded that the reaction 
time of 20 minutes was the more suitable for obtaining mainly the monoalkylated 
derivative and also some amount of the dialkylated derivative, to be used in the biological 
assays. 
 
3.1.1.1.3 Optimization of the amount of alkylating agent 
 
After optimizing the reaction time, the effect of increasing amounts of isopentyl 
iodide in the presence of the same amount of K2CO3 for the alkylation of baicalein after 20 
min of MW irradiation was studied (Table 5). 
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Table 5: Alkylation of baicalein with different quantities of isopentyl iodide. 
 
Conditions 0.8 equiv.a 1.2 equiv. a 1.6 equiv. a 2 equiv. a 
Baicaleinb 6.24 5.98 n.d. n.d. 
Biso1b 22.33 24.61 21.13 7.84 
Biso2b 0 0 0.97 1.27 
n.d.: trace quantities were detected but not determined 
a 1 equiv. is defined as the stoichiometric amount of isopentyl iodide in the presence of 5 equiv of K2CO3. 
b Yield determined assuming a similar molar extinction coefficient for all the compounds. 
 
According to Table 5 the reaction with 0.8 and 1.2 equiv. of isopentyl iodide 
provided the formation of the monoalkylated derivative (Biso1), without the formation of 
the dialkylated flavone (Biso2). The use of 1.2 equiv. leaded to a higher yield of Biso1 
and a higher consumption of baicalein (B) than when 0.8 equiv. were used. 
The use of 1.6 equiv. of isopentyl iodide provides a mixture of mono- and di- 
alkylated products (Biso1 and Biso2), with a yield of 21.13 % and 0.37 %, respectively. 
The quantification of the starting material was not possible since only trace amounts were 
detected and by-products have been formed with similar polarity. 
The relative yield of mono- and dialkylated products were different when 2 equiv. of 
isopentyl iodide were used. It was found a decrease in the yield of monoalkylated 
derivative and an increase of the yield of the dialkylated product (7.84% and 1.27%, 
respectively). In addition, once again only trace amounts of baicalein were detected. 
These results suggested that the dialkylated derivative was obtained by the alkylation of 
the monoalkylated derivative.  
Therefore, it was concluded that the optimal experimental conditions for achieving 
the objective proposed above would be 1.6 equivalents of isopentyl iodide for a 20 
minutes reaction. These conditions have become the reference for all the synthesis 
described in this work, with the different alkylating agents, both for baicalein (B), 3,7-
dihydroxyflavone (H) and chrysin (C), taking into account the scale-up conditions. 
 
 
 
Chapter 3: Results and Discussion 
67 
3.1.1.2. Derivatives of baicalein  
 
The synthetic approach used for the synthesis of alkylated derivatives of baicalein 
was based on the reaction of baicalein with 1.6 equivalent of the alkylating agent, namely, 
isopentyl, butyl, propyl, allyl, ethyl, or methyl iodide, in presence of anhydrous potassium 
carbonate using MAOS methodology. Table 6 summarizes the reaction conditions and the 
results obtained in the synthesis of baicalein alkyl-derivatives. 
 
Table 6: General conditions for the synthesis of alkylated derivatives of baicalein (B). 
 
Building block 
Reaction 
conditions 
Product Yield 
 
B 
isopentyl iodide, 
K2CO3, Me2CO, 3 h 
Biso1 
5.6% 
Biso2 
0.6% 
Butyl iodide, K2CO3, 
Me2CO, 2 h 
Butil1 
5.7% 
Butil2 
0.5% 
propyl iodide, 
K2CO3, Me2CO, 2 h 
 
Brop1 
6.0% 
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Brop2 
3.5% 
allyl iodide, 
K2CO3, Me2CO, 2 h 
 
Bali1 
4.2% 
 
Bali1’ 
1.1% 
ethyl iodide, 
K2CO3, Me2CO, 2 h 
Betil1 
4.5% 
methyl iodide, 
K2CO3, Me2CO, 2 h 
 
Bemet 1 
15% 
 
Bemet 2 
1.5% 
 
 
For almost all these reactions two alkylated derivatives were obtained. The major 
products were those with one alkyl side chain on the oxygen at position 7 (Biso1, Butil1, 
Brop1, Bali1, Betil1 and Bemet1), being the products with two alkyloxy side chains on C-
6 and C-7 (Biso2, Butil2, Brop2 and Bemet2) obtained as by-products. The higher yields 
obtained for monoalkylated derivatives in comparison with the yields obtained for 
dialkylated derivatives are in accordance with the results obtained in the HPLC studies in 
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section 3.1.1.1. and suggest that the first hydroxyl group to be alkylated is that on the para 
position to the carbonyl group (C7). 
However, the reaction of the baicalein with allyl iodide is one exception. The 
products of this reaction are two monoalkylated derivatives with one alkylated side chain 
on the oxygen at position 7 (Bali1) and one at position 6 (Bali1’). Once more by 
comparing the yields, it is suggested that the hydroxyl group at position 7 was the first to 
be alkylated.  
For all reactions the obtained yields were low (0.5-15%), being this explained by the 
fact of the reactions were incompleted and the formation in considerable amounts of more 
than one product, as illustrated in Figure 40 in section 3.1.1.1. 
 
3.1.1.3. Derivatives of 3,7-dihydroxyflavone 
 
The alkylated derivatives were obtained by the MW irradiation of 3,7-
dihydroxyflavone with 1.6 eq. of the alkylating agent (isopentyl, butyl, propyl, allyl, ethyl, 
and methyl iodide) or 2 eq. prenyl bromide in presence of anhydrous potassium 
carbonate. Table 7 summarizes the reaction conditions and the results obtained in the 
synthesis of 3,7-dihydroxyflavone alkyl-derivatives. 
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Table 7: General conditions for the synthesis of alkylated derivatives of 3,7-dihydroxyflavone (H). 
 
Building block 
Reaction 
conditions 
Product Yield 
 
H 
isopentyl iodide, 
K2CO3, Me2CO, 2 h 
 
Hiso 
12.9% 
butyl iodide, 
K2CO3, Me2CO, 2 h 
 
Hutil 1 
9.7% 
Hutil 2 
7.1% 
propyl iodide, 
K2CO3, Me2CO, 2 h 
 
Hrop 
3.7% 
allyl iodide, 
K2CO3, Me2CO, 2 h 
 
Hali 
9.3% 
ethyl iodide, 
K2CO3, Me2CO, 2 h 
 
Hetil 
1.7% 
methyl iodide, 
K2CO3, Me2CO, 2 h 
 
Hemet 
9.2% 
prenyl bromide, KI, 
K2CO3, Me2CO, 2 h 
 
Hrep 
7.4% 
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With this building block only the monoalkylated derivatives (Hiso, Hutil1, Hrop, 
Hali, Hetil, Hemet and Hrep) have been isolated, except for the reaction with butyl iodide, 
for which the dialkylated derivative (Hutil2) was also obtained. In fact, for all reactions 
although two derivatives were detected by TLC in the crude product, successive attempts 
of purification of the dialkylated derivatives by several methods (flash column 
chromatography, thin layer chromatography and crystallization) have failed to isolate the 
dialkylated derivatives. 
As already referred for the reactions with baicalein, the yield obtained for the 
monoalkylated derivative Hutil1 was slightly higher than the yield obtained for the 
dialkylated derivative Hutil2, suggesting that the hydroxyl group on the para position to 
the carbonyl group (C7) is the first to be alkylated. 
Incomplete reactions associated with the time consuming work-up procedure which 
involved column and preparative thin layer chromatography followed by crystallization 
justify the low yields of these reactions (1.7-12.9%).  
 
3.2.1.4. Derivatives of chrysin 
 
The synthetic approach used for the synthesis of alkylated derivatives was based on 
the reaction of chrysin (C) with 1.6 eq. of the isopentyl, butyl, propyl, allyl, ethyl, and 
methyl iodide or 2 eq. of the prenyl bromide in presence of anhydrous potassium 
carbonate using MAOS methodology. Table 8 summarizes the reaction conditions and the 
results obtained in the synthesis of chrysin alkyl-derivatives. 
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Table 8: General conditions for the synthesis of alkylated derivatives of Chrysin (C). 
 
Building block 
Reaction 
conditions 
Product Yield 
 
 
C 
isopentyl iodide, 
K2CO3, Me2CO, 1.5 h 
 
Ciso 
30% 
butyl iodide, 
K2CO3, Me2CO, 1.5 h 
 
Cutil 
29% 
propyl iodide, 
K2CO3, Me2CO, 1.5 h 
 
Crop 
22% 
allyl iodide, 
K2CO3, Me2CO, 1.5 h 
 
Cali 
31% 
ethyl iodide, 
K2CO3, Me2CO, 1.5 h 
 
Cetil 
32% 
methyl iodide, 
K2CO3, Me2CO, 1.5 h 
 
Cemet 
44% 
prenyl bromide, KI, 
K2CO3, Me2CO, 1.5 h 
 
Crep 
67 % 
 
Unlike reactions with other building blocks, as expected, only the monoalkylated 
derivatives possessing the alkyloxy group linked to C-7 (Ciso, Cutil, Crop, Cali, Cetil, 
Cemet and Crep) were obtained for reactions with chrysin, being this reflected in the 
higher yield of these reactions (22-67%). 
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3.1.2. Structure elucidation 
 
The structure elucidation of all alkylated flavonoids was established on the basis of 
IR, and NMR techniques. 13C NMR assignments were determined by 2D heteronuclear 
single quantum correlation (HSQC) and heteronuclear multiple bond correlation (HMBC) 
experiments. 
The numbering concerning the NMR assignments of alkyl groups is presented in 
Table 23 and the numbering relative to the NMR assignments of flavonoid scaffolds is 
presented in Figure 37. 
 
3.1.2.1. Derivatives of baicalein 
 
The IR data of all baicalein derivatives were in accordance with the performed 
molecular modification (Table 9). Accordingly, this spectra revealed the presence of at 
least one free hydroxyl group, attending that a large band of stretching vibration between 
3600–3300 cm-1 (hydroxyl groups) was visualized for all synthesized compounds, 
suggesting that the hydroxyl groups were not fully replaced. In addition, the observation of 
bands at 2961-2851 cm-1 (aliphatic C-H) on the IR spectra of baicalein derivatives, in 
contrast to their starting material, suggested the presence of alkyl groups. 
 
Table 9: IR data of baicalein (B) and its alkylated derivatives (Biso1, Biso2, Butil1, Butil2, Brop1, Brop2, 
Bali1, Bali1', Betil1, Bemet1 and Bemet2). 
 
Groups 
ʋ (cm-1) 
B Biso1 Biso2 Butil1 Butil2 Brop1 
OH 
3500-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
Aliphatic 
C-H 
- 
2955 
2921 
2854 
2957 
2922 
2851 
2956 
2923 
2873 
2961 
2925 
2851 
2927 
2922 
2851 
C=O 1651 1657 1653 1655 1657 1617 
Aromatic 
C=C 
1609 
1573 
1498 
1462 
1489 
1477 
1450 
1559 
1497 
1457 
1419 
1502 
1584 
1464 
1451 
1497 
1457 
1419 
1559 
1489 
1473 
1459 
C-O 1287 1115 1120 1191 1121 1125 
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Table 9 (contd.): IR data of baicalein (B) and its alkylated derivatives (Biso1, Biso2, Butil1, Butil2, Brop1, 
Brop2, Bali1, Bali1', Betil1, Betil2, Bemet1 and Bemet2). 
 
Groups 
ʋ (cm-1) 
Brop2 Bali1 Bali1’ Betil1 Bemet1 Bemet2 
OH 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
Aliphatic 
C-H 
2965 
2921 
2851 
2925 
2923 
2854 
2925 
2923 
2854 
2952 
2922 
 
2922 
 
 
2922 
 
C=O 1657 1663 1664 1653 1631 1634 
Aromatic 
C=C 
1499 
1470 
1458 
1576 
1489 
1449 
1585 
1489 
1451 
1559 
1507 
1457 
1467 1457 
C-O 1122 1252 1115 1189 1131 1129 
 
 
The 1H and 13C NMR data of baicalein (B) and alkyl-derivatives (Biso1, Biso2, 
Butil1, Butil2, Brop1, Brop2, Bali1, Bali1’, Betil1, Bemet1 and Bemet2) are reported in 
Table 10 and Table 11, respectively. 
The 1H NMR spectra of baicalein (B) derivatives showed that all of them have a 
non-substituted B-ring (H-2’, 6’: δH 7.91-7.87 m; H-3’, 4’, 5’: δH 7.58-7.49 m) as the 
precursor B. Like the flavone B, 1H NMR spectra of all derivatives showed a signal at δH 
6.69-6.67 s corresponding to H-3, and a signal at δH 6.63-6.55 s corresponding to H-8. For 
most derivatives, namely Biso2, Brop1, Brop2, Bali1, Bali1’, Betil1, and Bemet1 a 
hydrogen-bonded hydroxyl group at C-5 (δH 13.04-12.50 s) was also observed, like for the 
starting material B. Besides these, for derivatives Biso1, Brop1, Betil1 and Bemet1 the 
signal of the hydroxyl group at C6 (δH 5.37-5.35 s) was also observed. These data 
confirms that neither of these positions is substituted. 
Considering Biso1 and Biso2 the 1H NMR and 13C NMR spectra showed 
characteristic signals of one or two isopentyl groups (δH: 4.18-4.06 t, 1.93-1.65 m, 1.96-
1.23 m, 1.01-0.97 d; δC: 71.8-67.5, 38.9-37.5, 29.8-29.3, 22.7-22.6, 22.6-22.5) 
respectively (Table 10 and Table 11). Although, the signal of the hydroxyl group at C-6 
was observed for the flavone Biso1, the correspondent signal was not observed for the 
derivative Biso2, suggesting that the second isopentyl group should be linked to the 
hydroxyl group at position 6. For Biso1 the position of the isopentyl side chain on flavone 
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skeleton was confirmed by the correlations observed on the HMBC spectra between the 
proton signals of the oxymethylene group (δH 4.18 t) and the carbon signal of C-7 (δC 
152.3). For Biso2 a similar correlation was observed for the proton signals of the 
oxymethylene groups (δH: 4.12 t and 4.06 t) and the carbon signals of C-7 (δC 158.9) and 
C-6 (δC 131.9), respectively (Figure 41). 
 
 
Figure 41: Main connectivities found in the HMBC of derivatives Biso1 and Biso2. 
 
For derivatives Butil1 and Butil2, the 1H and 13C NMR spectra put in evidence the 
presence of one or two butyl side chains at positions 6 or 7 (Table 10 and Table 11). This 
group was evidenced by the signals of one oxymethylene group (δH 4.16-4.05 t, δC 73.1-
69.3), two methylenic groups (δH 1.94-1.73 m and δH 1.62-1.48 m, δC 32.2-31.0 and δC 
19.2) and one methylic group (δH 1.02-0.97 t, δC 13.9-13.8). As Butil1 was the major 
product of the nucleophilic substitution reaction it was proposed that this compound 
should result from the substitution at position 7. On the contrary Butil2 should result from 
the substitution at position 6. This hypothesis was confirmed by the correlation observed 
in the HMBC spectrum of Butil1 and Butil2 (Figure 42).  
 
 
Figure 42: Main connectivities found in the HMBC of derivatives Butil1 and Butil2. 
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Regarding Brop1 the 1H NMR spectra displayed two triplets at δH 4.12 (2H) and δH 
1.10 (3H), and one multiplet at δH 2.05-1.98 m (2H), suggesting the presence of a 
propyloxy side chain at C-7. Instead, for Brop2 the 1H NMR spectra showed four triplets 
at δH 4.05 (2H), δH 4.01 (2H), δH 1.10 (3H), and δH 1.06 (3H) and two multiplets at δH 1.96-
1.89 (2H) and δH 1.85-1.78 (2H), revealing the presence of two propyloxy groups linked to 
flavone scaffold. Additionally, the signal of the hydroxyl group at C-6 was observed for the 
flavone Brop1. However, the correspondent signal was not observed for the derivative 
Brop2, suggesting that the second propyloxy group should be at position 6. For both 
propyl derivatives, the linkage of propyloxy groups to C-7 was confirmed by the 
correlations observed on the HMBC spectra between the proton signals of the 
oxymethylene group at δH 4.12 and δH 4.05 and the carbon signals of C-7 δC 152.3 and δC 
158.8, respectively) (Figure 43) The linkage of propyloxy group to C-6 for compound 
Brop2 was also confirmed by the correlation between the proton signals at δH 4.01 t and 
the carbon signal of C-6 (δC 132.0) (Figure 43). 
 
 
Figure 43: Main connectivities found in the HMBC of derivatives Brop1 and Brop2. 
 
For derivatives Bali1 and Bali1’, the 1H and 13C NMR spectra showed signals that 
put in evidence the presence of one allyloxy group at positions 6 or 7 (Table 10 and Table 
11). This group was evidenced by the signals of one oxymethylene group (δH 4.77-4.74 d, 
δC 73.7-70.2), one olephynic proton at δH 6.18 -6.01 m linked to a carbon at δC 133.0-
131.8, other olephinic carbon at δC 120.0-119.1 which is linked to two olephynic protons 
(δH 5.51-5.28 m). As Bali1 was the major product of the nucleophilic substitution reaction 
it was proposed that this compound should result from the substitution at position 7. On 
the contrary Bali1’ should result from the substitution at position 6. This hypothesis was 
confirmed by the correlation observed in the HMBC spectrum of Bali1 and Bali1’ (Figure 
44). 
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Figure 44: Main connectivities found in the HMBC of derivatives Bali1 and Bali1'. 
 
Considering Betil1 the 1H NMR and 13C NMR spectra showed characteristic signals 
of one ethyl group (δH 4.24 q, 1.55 t; δC 65.2, 14.6) (Table 10 and Table 11). The 
correlations observed on the HMBC spectra between the proton signals of the 
oxymethylene group (δH 4.24 q) and the carbon signal of C-7 (δC 152.2) confirmed the 
position of this side chain on the flavone skeleton (Figure 45).  
 
 
Figure 45: Main connectivities found in the HMBC spectrum of derivative Betil1. 
 
Regarding Bemet1 the 1H and 13C NMR spectra displayed the presence of signals 
characteristic of one methoxyl group (δH 3.94 s, δC 60.9) confirming the methylation of one 
hydroxyl group of the flavone scaffold. Instead, for Bemet2 the 1H and 13C NMR spectra 
showed signals of two methoxyl groups (δH 3.93-3.98 s, δC 56.4-66.9) revealing the 
methylation of both hydroxyl groups at C-6 and C-7. For both methyl derivatives, the 
linkage of methoxyl groups to C-7 was confirmed by the correlations observed on the 
HMBC spectra between the proton signals of the methoxyl group δH 3.94 and δH 3.98 and 
the carbon signals of C-7 (δC 153.1 and δC 159.0) (Figure 46). The linkage of methoxyl 
group to C-6 for compound Bemet2 was also confirmed by the correlation between the 
proton signals at δH 3.93 s and the carbon signal of C-6 (δC 132.7) (Figure 46). 
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Figure 46: Main connectivities found in the HMBC of derivatives Bemet1 and Bemet2. 
 
For derivatives Brop2, Butil2, Bali1, Bemet1 and Bemet2 the 1H and 13C NMR 
data are in accordance to the published data. 183-185 
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Table 10: 1H NMR data of baicalein (B) and its alkylated derivatives (Biso1, Biso2, Butil1, Butil2, Brop1, Brop2, Bali1, Bali1’, Betil1, Bemet1 and Bemet2). 
 
 B Biso1 Biso2 Butil1 Butil2 Brop1 
H-2’,6’ 7.92-7.88 (m) 7.91-7.88 (m) 7.91-7.88 (m) 7.91-7.87 (m) 7.91-7.88 (m) 7.91-7.88 (m) 
H-3’,4’,5’ 7.60-7.52 (m) 7.54-7-52 (m) 7.54-7.52 (m) 7.54-7.52 (m) 7.54-7.52 (m) 7.55-7.52 (m) 
H-3 6.64 (s) 6.69 (s) 6.67 (s) 6.68 (s) 6.67 (s) 6.69 (s) 
H-5 12.72 (OH, s) n.o 12.61 (OH,s) n.o n.o. 12.50 (OH,s) 
H-6 n.o. 5.35 (OH,s) - n.o - 5.37 (OH,s) 
H-7 n.o. - - - - - 
H-8 6.60 (s) 6.62 (s) 6.56 (s) 6.61 (s) 6.55 (s) 6.61 (s) 
H-1’’ — 4.18 (t, J=6.6) 4.12 (t, J=6.5) 4.16 (t, J=6.6) 4.09 (t, J=6.5) 4.12 (t, J=6.9) 
H-2’’ — 1.93-1.77 (m) 1.82-1.75 (m) 1.94-1.85 (m) 1.93-1.83 (m) 2.05-1.98 (m) 
H-3’’ — 1.29-1.23 (m) 1.96-1.84 (m) 1.61-1.48 (m) 1.62-1.48 (m) 1.10 (t, J=7.4) 
H-4’’ — 
1.01 (d, J=6.3) 1.00 (d, J= 6.5) 
1.02 (t, J=7.4) 1.02 (t, J=7.4) - 
H-5’’ — - - - 
H-1’’’ —  4.06 (t, J=6.9) - 4.05 (t, J=6.6) - 
H-2’’’ —  1.72-1.65 (m) - 1.82-1.73 (m) - 
H-3’’’ —  1.96-1.84 (m) - 1.62-1.48 (m) - 
H-4’’’ —  
0.97 (d, J=6.6) 
- 0,97 (t, J=7.4) - 
H-5’’’ —  - - - 
n.o. not observed; Values in parts per million (δH). Measured in CDCl3 at 300.13 MHz. J values (Hz) are presented in parentheses. 
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Table 10 (Contd.): 1H NMR data of baicalein (B) and its alkylated derivatives (Biso1, Biso2, Butil1, Butil2, Brop1, Brop2, Bali1, Bali1’, Betil1, Bemet1 and Bemet2). 
 
 Brop2 Bali1 Bali1’ Betil1 Bemet1 Bemet2 
H-2’,6’ 7.90-7.88 (m) 7.90-7.87 (m) 7.90-7.87 (m) 7.91-7.88 (m) 7.92-7.89 (m) 7.92-7.95 (m) 
H-3’,4’,5’ 7.54-7.52 (m) 7.58-7.49 (m) 7.56-7.52 (m) 7.55-7.52 (m) 7.55-7.53 (m) 7.57-7.52 (m) 
H-3 6.67 (s) 6.68 (s) 6.67 (s) 6.69 (s) 6.69 (s) 6.68 (s) 
H-5 12.50 (OH,s) 13.04 (OH,s) 13.04 (OH,s) 12.55 (OH, s) 12.69 (OH, s) 12.69 (OH, s) 
H-6 - n.o. - 5.37 (OH,brs) 5.35 (OH,brs) - 
H-7 - - n.o. - - - 
H-8 6.55 (s) 6.63 (s) 6.62 (s) 6.61 (s) 6.58 (s) 6.58 (s) 
H-1’’ 4.05 (t, J=6.5) 4.74 (brd, J=5.4) 4.77 (dt, J=5.3, 1.2) 4.24 (q, J=7.0) 3.94 (s) 3.98 (s) 
H-2’’ 1.96-1.89 (m) 6.18-6.05 (m) 6.14-6.01 (m) 1.55 (t, J=7.0) - - 
H-3’’ 1.10 (t, J=7.4) 
5.51-5.45 (m) 
5.41-5.37 (m) 
5.44-5.37 (m) 
5.32-5.28 (m) 
- - - 
H-4’’ - - - - - - 
H-5’’ - - - - - - 
H-1’’’ 4.01 (t, J=6.7) - - - - 3.93 (s) 
H-2’’’ 1.85-1.78 (m) - - - - - 
H-3’’’ 1.06 (t, J=7.4) - - - - - 
n.o. not observed; Values in parts per million (δH). Measured in CDCl3 at 300.13 MHz. J values (Hz) are presented in parentheses. 
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Table 11: 13C NMR data of baicalein (B) and its alkylated derivatives (Biso1, Biso2, Butil1, Butil2, Brop1, 
Brop2, Bali1, Bali1’, Betil1, Bemet1 and Bemet2). 
 
 B Biso1 Biso2 Butil1 Butil2 Brop1 
C1’ 130.9 131.5 131.7 131.5 131.6 131.6 
C2’ 125.6 126.2 126.2 126.3 126.3 126.2 
C3’ 128.5 129.1 129.1 129.1 129.1 129.1 
C4’ 131.1 131.8 131.7 131.8 131.8 131.7 
C5’ 128.5 129.1 129.1 129.1 129.1 129.1 
C6’ 125.6 126.2 126.2 126.3 126.3 126.2 
C2 163.0 164.0 163.9 164.0 163.8 164.0 
C3 104.2 105.4 105.6 105.4 105.6 105.4 
C4 182.0 182.7 182.7 182.7 182.7 182.7 
C4a 104.4 106.0 106.3 106.0 106.1 106.0 
C5 146.5 145.6 145.7 145.7 147.4 145.6 
C6 128.7 129.7 131.9 129.7 132.1 129.7 
C7 152.8 152.3 158.9 152.3 158.9 152.3 
C8 93.7 91.0 91.2 91.1 91.3 91.1 
C8a 150.0 150.7 153.3 150.7 153.2 150.7 
C1’’ - 68.0 67.5 69.3 68.9 71.0 
C2’’ - 37.5 37.6 31.0 31.0 22.3 
C3’’ - 29.7 29.3 19.2 19.2 10.4 
C4’’ - 22.7 22.6 13.8 13.8 - 
C5’’ - 22.6 22.5 - - - 
C1’’’ - - 71.8 - 73.1 - 
C2’’’ - - 38.9 - 32.2 - 
C3’’’ - - 29.8 - 19.2 - 
C4’’’ - - 22.7 - 13.9 - 
C5’’’ - - 22.6 - - - 
Values in parts per million (δC). Measured in CDCl3 at 75.47 MHz. 
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Table 11 (Contd.): 13C NMR data of baicalein (B) and its alkylated derivatives (Biso1, Biso2, Butil1, Butil2, 
Brop1, Brop2, Bali1, Bali1’, Betil1, Bemet1 and Bemet2). 
 
 Brop2 Bali1 Bali1’ Betil1 Bemet1 Bemet2 
C1’ 131.4 131.4 131.3 131.5 131.3 131.3 
C2’ 126.2 126.2 126.3 126.3 126.3 126.3 
C3’ 129.1 129.1 129.1 129.1 129.1 129.1 
C4’ 131.7 131.8 131.9 131.8 131.9 131.9 
C5’ 129.1 129.1 129.1 129.1 129.1 129.1 
C6’ 126.2 126.2 126.3 126.3 126.3 126.3 
C2 163.8 164.1 164.1 164.1 164.0 164.0 
C3 105.6 105.4 105.3 105.5 105.7 105.7 
C4 182.7 182.6 183.0 182.7 182.8 182.8 
C4a 106.1 106.1 106.1 106.0 106.1 106.3 
C5 140.0 145.8 152.1 145.7 145.5 153.1 
C6 132.0 129.8 128.7 129.7 129.7 132.7 
C7 158.8 151.7 155.5 152.2 153.1 159.0 
C8 91.2 91.6 93.4 91.1 90.7 90.7 
C8a 153.2 150.5 153.3 150.7 151.1 153.4 
C1’’ 70.6 70.2 73.7 65.2 60.9 56.4 
C2’’ 22.3 131.8 133.0 14.6 - . 
C3’’ 10.4 119.1 120.0 - - . 
C4’’ - - - - - . 
C5’’ - - - - - . 
C1’’’ 75.0 - - - - 66.9 
C2’’’ 22.7 - - - - . 
C3’’’ 10.5 - - - - . 
C4’’’ - - - - - . 
C5’’’ - - - - - . 
Values in parts per million (δC). Measured in CDCl3 at 75.47 MHz or 125.77 MHz 
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3.1.2.2. Derivatives of 3,7-dihydroxyflavone  
 
The IR data of 3,7-dihydroxyflavone (H) and its alkylated derivatives are presented 
in Table 12. The presence of alkyl groups was suggested by the observation of bands at 
2999-2854 cm-1. Additionally, the presence of one free hydroxyl group was revealed by 
the presence of a large band of stretching vibration between 3600-3100 cm-1, for all 
synthesized compounds except for Hutil2, suggesting that alkylation of both hydroxyl 
groups have occurred only for Hutil2. 
 
Table 12: IR data of 3,7-dihydroxyflavone (H)  and its alkylated derivatives (Hiso, Hutil1, Hutil2, Hrop, Hali, 
Hetil, Hemet and Hrep). 
 
Groups 
ʋ (cm-1) 
H Hiso Hutil1 Hutil2 Hrop Hali Hetil Hemet Hrep 
OH 
3400-
3100 
3600-
3300 
3600-
3300 
- 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
3600-
3300 
Aliphatic 
C-H 
- 
2958 
2921 
2854 
2958 
2922 
2854 
2958 
2936 
2873 
2970 
2920 
2999 
2964 
2921 
2026 2922 
2974 
2920 
2854 
C=O 1623 1605 1604 1623 1603 1615 1614 1622 1613 
Aromatic 
C=C 
1571 
1451 
1414 
1504 
1467 
1452 
1410 
1566 
1462 
1452 
1419 
1499 
1466 
1447 
1567 
1504 
1432 
1412 
1564 
1503 
1473 
1453 
1504 
1457 
1408 
1508 
1456 
1401 
1566 
1463 
1451 
1408 
C-O 1280 1260 1250 1260 1259 1260 1262 1262 1258 
 
The 1H and 13C NMR data of 3,7-dihydroxyflavone (H) and alkyl-derivatives (Hiso, 
Hutil1, Hutil2, Hrop, Hali, Hetil, Hemet and Hrep) are reported in Table 13 and Table 
14. 
The 1H NMR spectra of 3,7-dihydroxyflavone (H) derivatives demonstrated that all of 
them have a non-substituted B-ring (H-2’,6’: δH 8.25-8.07 m; H-3’, 4’, 5’: δH 7.61-7.42 m) 
as the precursor H. Moreover, three signals of A ring aromatic protons had been found 
namely signals for H-5 (δH 8.15-8.12 d), H-6 (δH 7.03-6.96 dd), and H-8 (δH 6.97-6.90 d), 
like the starting material (H) (δH 8.04 d, δH 6.96 m and δH 6.93 m, respectively). 
Like for baicalein (B) derivatives, in addition to the signals described before, the 1H 
and 13C NMR spectra of all 3,7-dihydroxyflavone (H) derivatives showed signals that put in 
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evidence the presence of one alkyl side chain, except for derivative Hutil2, for which 
characteristic signals of two butyl side chains are observed, as illustrated in Figure 47. 
 
 
Figure 47: 1H and 13C NMR data for the alkyl groups of derivatives Hiso (A), Hutil1/2 (B), Hrop (C), Hali (D), 
Hetil (E), Hemet (F) and prenyl group of derivative Hrep (G). 
 
The structure of Hrep was confirmed by comparison with the 1H and 13C NMR data 
previously reported.171 
 
For all derivatives, the position of alkyl side chains was evidenced by the 
correlations found in the HMBC spectra between the proton signals of the methylene 
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groups (H-1”, H-1”’) and the carbon signals of C7 (δC 163.9-162.9) and C3 (δC 140.5-
137.1), respectively (Figure 48). 
 
 
Figure 48: Main connectivities found in the HMBC of alkylated derivatives of 3,7-dihydroxyflavone (Hiso (A), 
Hutil1 (B),Hutil2 (C), Hrop (D), Hali (E), Hetil (F), Hemet (G) and Hrep (H)).
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Table 13: 1H NMR data of 3,7-dihydroxyflavone (H) and its alkylated derivatives (Hiso, Hutil1, Hutil2, Hrop, Hali, Hetil, Hemet and Hrep). 
 
 H Hiso Hutil1 Hutil2 Hrop Hali Hetil Hemet Hrep 
H-2’,6’ 8.24-8.21 (m) 8.25- 8.23 (m) 8.25-8.22 (m) 8.10-8.07 (m) 8.25-8.22 (m) 8.25-8.22 (m) 8.25-8.22 (m) 8.24-8.21 (m) 8.25-8.22 (m) 
H-3’,4’,5’ 7.53-7.43 (m) 7.56-7.42 (m) 7.56-7.43 (m) 7.52-7.49 (m) 7.61-7.43 (m) 7.61-7.43 (m) 7.56-7.43 (m) 7.55-7.42 (m) 7.56-7.43 (m) 
H-3 n.o. n.o. n.o. - n.o. n.o. n.o. n.o. n.o. 
H-5 8.04 (d, J=8.0) 8.12 (d, J=8.9) 8.13 (d, J=8.6) 8.14 (d, J=8.9) 8.13 (d, J=8.9) 8.15 (d, J= 8.9) 8.13 (d, J= 8,9) 8.13 (d, J=8.9) 8.13 (d, J=8.8) 
H-6 6.96 (m) 6.98 (dd, 
J=8.9, 2.3) 
7.00 (dd, 
J=8.8, 2.3) 
6.96 (dd, 
J=8.9, 2.3) 
7.00 (dd, 
J=10.4, 2.3) 
7.03 ( dd, 
J= 8.6, 2.3) 
6.99 (dd, 
J=8.9, 2.1) 
6.99 (dd, 
J=8.9, 2.3) 
7.00 (dd, 
J=8.8, 2.2) 
H-7  - - - - - - - - 
H-8 6.93 (m) 6.94 (d, J=2.2) 6.95 (d, J=2.3) 6.90 (d, J=2.3) 6.97 (d, J=2.3) 6.97 (d, J=2.3) 6.95 (d, J=2.1) 6.94 (d, J=2.3) 6.97 (d, J=2.2) 
H-1’’ - 4.11 (t, J=6.6) 4.09 (t, J=6.5) 4,06 (t, J=6.5) 4.05 (t, J=6.6) 4.67 (dt, J=5.3, 
1.5) 
4.17 (q, 6.9) 3.93 (s) 4.64 (d, J=6.8) 
H-2’’ — 1.78-1.72 (m) 1.89-1.80 (m) 1.87-1.78 (m) 1.95-1.83 (m) 6.16-6.03 (m) 1.50 (t, J=6.9) - 5.53 (t, J=6.8, 
2.0) 
H-3’’ — 1.92-1.81 (m) 1.60-1.47 (m) 1.59-1.49 (m) 1.09 (t, J=7.4) 5.52-5.44 (m) 
5.40-5.31 (m) 
- - - 
H-4’’ — 1.00 (d, J= 
6.5) 
1.01 (t, J=7.4) 1.00 (t, J=7.4) - - - - 1.84 (s) 
H-5’’ — - - - - - - 1.80 (s) 
H-1’’’ — - - 4.02 (t, J=6.5) - - - - - 
H-2’’’ — - - 1.73-1.63 (m) - - - - - 
H-3’’’ — - - 1.42-1.32 (m) - - - - - 
H-4’’’ — - - 0.87 (t, J=7.4) - - - - - 
H-5’’’ _ - - - - - - - - 
n.o. not observed; Values in parts per million (δH). Measured in CDCl3 at 300.13 MHz. J values (Hz) are presented in parentheses. 
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Table 14: 13C NMR data of 3,7-dihydroxyflavone (H) and its alkylated derivatives (Hiso, Hutil1, Hutil2, Hrop, 
Hali, Hetil, Hemet and Hrep). 
 
 H Hiso Hutil1 Hutil2 Hrop Hali Hetil Hemet Hrep 
C1’ 131.0 131.3 131.3 131.3 131.3 131.2 131.3 131.2 131.3 
C2’ 127.0 127.5 127.5 128.5 127.5 127.5 127.5 127.5 127.5 
C3’ 127.9 128.6 128.9 128.3 128.6 128.6 128.8 128.6 128.6 
C4’ 129.1 129.9 130.2 130.4 129.9 129.9 129.9 129.9 129.9 
C5’ 127.9 128.6 128.9 128.3 128.6 128.6 128.8 128.6 128.6 
C6’ 127.0 127.5 127.5 128.5 127.5 127.5 127.5 127.5 127.5 
C2 143.5 144.1 143.1 155.3 144.1 144.1 144.1 144.2 144.2 
C3 137.7 138.1 137.1 140.5 138.1 138.1 138.1 138.1 139.5 
C4 172.4 172.9 206.0 174.8 172.9 172.8 172.9 172.8 207.0 
C4a 113.5 115.1 113.4 118.0 114.4 114.7 114.4 114,6 114.7 
C5 126.2 126.7 126.5 127.1 126.7 126.8 126.7 126.8 126.7 
C6 114.7 115.3 114.2 114.8 115.3 115.2 115.2 114.9 115.4 
C7 162.4 163.9 162.9 163.6 163.9 163.2 163.7 164.3 163.6 
C8 101.9 100.3 99.3 100.3 100.3 100.8 100.3 99.8 100.6 
C8a 156.7 157.4 156.4 157.1 157.4 157.3 157.4 157.4 157.4 
C1’’ - 67.2 67.4 68.4 70.3 69.6 64.3 53.9 65.5 
C2’’ - 37.6 29.9 31.0 22.4 131.9 14.6 - 118.5 
C3’’ - 25.1 18.2 19.1 10.5 118.6 - - 31.0 
C4’’ - 
22.6 
12.8 13.8 - - - - 25.9 
C5’’ - - - - - - - 18.3 
C1’’’ -  - 72.6 - - - - - 
C2’’’ -  - 32.1 - - - - - 
C3’’’ -  - 19.2 - - - - - 
C4’’’ -  - 13.8 - - - - - 
C5’’’ -  - - - - - - - 
Values in parts per million (δC). Measured in CDCl3 at 75.47 MHz.
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3.1.2.3. Derivatives of chrysin  
 
The IR data of chrysin (C) as well as chrysin derivates (Ciso, Cutil, Crop, Cali, 
Cetil, Cemet and Crep) are presented in Table 15. The observation of bands at 2985-
2851 cm -1 (aliphatic C-H), suggested the presence of alkyl groups. The presence of a 
large band of stretching vibration at 3451-3441 cm -1 corresponding to hydroxyl groups is 
an indicator that the alkylation did not occur at both hydroxyl groups of the precursor (C). 
 
Table 15: IR data of chrysin (C) and its alkylated derivatives (Ciso, Cutil, Crop, Cali, Cetil, Cemet and Crep). 
 
Groups 
ʋ(cm-1) 
C Ciso Cutil Crop Cali Cetil Cemet Crep 
OH 
3600-
3400 
3600-
3400 
3600-
3400 
3600-
3400 
3600-
3400 
3600-
3400 
3600-
3400 
3600-
3400 
Aliphatic 
C-H 
- 
2956 
2921 
2851 
2952 
2933 
2868 
2964 
2920 
2874 
2961 
2920 
2851 
2985 
2924 
2852 
2923 
2854 
2967 
2917 
2853 
C=O 1652 1662 1664 1661 1665 1663 1668 1659 
Aromatic 
C=C 
1577 
1555 
1499 
1588 
1452 
 
1589 
1569 
1450 
1442 
1585 
1569 
1507 
1451 
1586 
1506 
1451 
 
1586 
1509 
1454 
1588 
1495 
1452 
1436 
1588 
1504 
1449 
C-O 1168 1169 1170 1173 1170 1173 1160 1178 
 
The 1H and 13C NMR data of chrysin (C) and its alkyl-derivatives (Ciso, Cutil, Crop, 
Cali, Cetil, Cemet and Crep) are reported in Table 16 andTable 17. 
The 1H NMR spectra of chrysin (C) derivatives indicated that all of them have a non-
substituted B-ring (H-2’,6’ δH 7.91-7.82 m; H-3’,4’,5’ δH 7.58-7.48 m) as the precursor C. 
Like for chrysin (C), the 1H NMR spectra showed signals for two A-ring aromatic protons 
(H-6: δH 6.40-6.33 d, H-8: δH 6.53-6.46 d) and a signal at δH 6.68-6.61 s corresponding to 
H-3. In addition, the signal of the hydroxyl group at C-5 (δH 12.73-12.69 s) was also 
observed for all derivatives, except for Cutil and Cetil. 
Besides these signals, the 1H and 13C NMR spectra of chrysin (C) derivatives 
showed characteristic signals of one prenyl (Crep), isopentyl (Ciso), butyl (Cutil), propyl 
(Crop), allyl (Cali), ethyl (Cetil), or methyl (Cemet) side chain, as illustrated in Figure 49. 
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Figure 49:1H and 13C NMR data for the alkyl groups of derivatives Ciso (A), Cutil (B), Crop (C), Cali (D), 
Cetil (E), Cemet (F) and prenyl group of derivative Crep (G). 
 
The position of these side chains was evidenced by the correlations found in the 
HMBC as indicated in Figure 50. 
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Figure 50: Main connectivities found in the HMBC of alkylated derivatives of chrysin (Ciso (A), Cutil (B), Crop 
(C), Cali (D), Cetil (E), Cemet (F) and Crep (G)). 
 
For derivatives Cali, Cetil and Cemet, the 1H and 13C NMR data obtained are in 
accordance to the published data. 186-188  
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Table 16: 1H NMR data of chrysin (C) and its alkylated derivatives (Ciso, Cutil, Crop, Cali, Cetil, Cemet and Crep). 
 
 C Ciso Cutil Crop Cali Cetil Cemet Crep 
H-2’,6’ 7.90-7.87 (m) 7.90-7.88 m 7.87-7.84 (m) 7.90-7.87 (m) 7.90-7.88 (m) 7.89-7.86 (m) 7.91-7.88 (m) 7.86-7.82 (m) 
H-3’,4’,5’ 7.55-7.52 (m) 7.55-7.52 (m) 7.52-7.50 (m) 7.56-7.49 (m) 7.58-7.51 (m) 7.53-7.51 (m) 7.55-7.52 (m) 7.51-7.48 (m) 
H-3 6.67 (s) 6.67 (s) 6.63 (s) 6.66 (s) 6.68 (s) 6.65 (s) 6.67 (s) 6.61 (s) 
H-5 12.70 (OH, s) 12.71 (OH,s) n.o. 12.70 (OH,s) 12.72 (OH,s) n.o. 12.73 (OH,s) 12.69 (OH,s) 
H-6 6.30 (d, J=2.2) 6.37 (d, J=2.2) 6.34 (d, J=2.2) 6.37 (d, J=2.2) 6.40 (d, J=2.2) 6.35 (d, J=2.2) 6.38 (d, J=2.3) 6.33 (d, J=2.2) 
H-7 6.14 (OH,s) - - - - - - - 
H-8 6.48 (d, J=2.2) 6.50 (d, J=2.2) 6.47 (d, J=2.2) 6.50 (d, J=2.2) 6.53 (d, J=2.2) 6.48 (d, J=2.2) 6.51 (d, J=2.3) 6.46 (d, J=2.2) 
H-1’’  4.07 (t, J=6.6) 4.02 (t, J=6.5) 4.00(t, J=6.6) 
4.63 (dt, J=5.2, 
1.4) 
4.10 (q, J=7.0) 3.89 (s) 4.56 (d, J=6.9) 
H-2’’  1.75-1.68 (m) 1.84-1.75 (m) 1.90-1.79 (m) 6.10-6.02 (m) 1.45 (t, J=7.0) - 5.48 (t, J=6.7) 
H-3’’  1.92-1.78 (m) 1.56-1.44 (m) 1.06 (t, J= 7.4) 
5.48-5.44 (m) 
5.37-5.34 (m) 
- - - 
H-4’’  
0.98 (d, J=6.5) 
0.99 (t, J=7.4)  - - - 1.81 (s) 
H-5’’  - - - - - 1.76 (s) 
n.o. not observed; Values in parts per million (δH). Measured in CDCl3 at 300.13 MHz or 500 MHz. J values (Hz) are presented in parentheses. 
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Table 17: 13C NMR data of Chrysin (C) and its alkylated derivatives (Ciso, Cutil, Crop, Cali, Cetil, Cemet 
and Crep). 
 
 C Ciso Cutil Crop Cali Cetil Cemet Crep 
C1’ 131.9 131.8 131.3 131.4 131.4 131.3 131.3 131.2 
C2’ 126.3 126.3 126.2 126.3 126.3 126.3 126.3 126.2 
C3’ 129.1 129.1 129.1 129.1 129.1 129.1 129.1 129.0 
C4’ 131.9 131.8 131.8 131.8 131.9 131.8 131.9 131.8 
C5’ 129.1 129.1 129.1 129.1 129.1 129.1 129.1 129.0 
C6’ 126.3 126.3 126.2 126.3 126.3 126.3 126.3 126.2 
C2 163.9 163.9 163.8 163.9 164.0 163.9 164.0 163.8 
C3 105.9 105.9 105.8 105.9 105.9 105.8 105.9 105.7 
C4 182.4 182.5 182.4 182.5 182.5 182.5 182.5 182.4 
C4a 105.6 105.6 105.5 105.6 105.8 105.6 105.7 105.6 
C5 162.0 162.1 162.1 162.1 162.2 162.1 162.2 162.0 
C6 99.5 98.6 98.6 98.6 98.8 98.6 98.2 98.8 
C7 165.0 168.2 165.2 165.2 164.6 165.0 165.6 164.9 
C8 94.2 93.1 93.0 93.1 93.4 93.1 92.7 93.2 
C8a 157.8 158.0 157.8 157.8 157.8 157.8 157.8 157.7 
C1’’ - 67.1 68.4 70.2 69.3 64.2 55.8 65.5 
C2’’ - 25.0 31.0 22.3 132.1 14.6 - 118.6 
C3’’ - 37.6 19.2 10.4 118.5 - - 139.2 
C4’’ - 
22.5 
13.8 - - - - 25.8 
C5’’ - - - - - - 18.3 
Values in parts per million (δC). Measured in CDCl3 at 75.47 MHz or 125.77 MHz
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3.2. Peck purity  
 
For baicalein (B) derivatives Biso1, Brop1 and Bali1, prior to their biological activity 
evaluation, their purity was evaluated by HPLC-DAD as described in chapter 5. A 
percentage of purity greater than 95% was found for all derivatives (Table 18).  
 
Table 18: Purity values of the alkylated derivatives of baicalein (Biso1, Brop1 and Bali1). 
 
Compound Peak purity 
Biso1 99.7% 
Brop1 99.7% 
Bali1 99.8% 
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3.3. Biological activity 
 
3.3.1. Modulation of procaspase-3 and -7 activity* 
 
In this section it is discussed the results obtained in the evaluation of the 
procaspases-3 and -7 modulatory activity of some synthesized flavonoids (the alkylated 
derivatives Biso1, Brop1 and Bali1).  
The effect of the derivatives Biso1, Brop1 and Bali1 on the activity of human 
procaspases-3 and -7 was evaluated using yeast cell assays. In this yeast assay, the 
expression of procaspases-3 and -7 does not affect the yeast growth, but activators of 
procaspases-3 and -7, such as PAC-1 (positive control33) induce yeast growth inhibition. 
Using this approach, the effect of 0.1-50 µM PAC-1 and 0.1-15 µM flavonoids on the 
growth of yeast individually expressing procaspases-3 or -7 was evaluated and the 
percentage of drug-induced growth inhibition was estimated, considering 100% growth the 
number of colony-forming units (c.f.u.) obtained with DMSO only. The results are 
summarized in Figure 51. 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
*Work developed by the Master student Sofia Salazar under the supervision of Professor Lucília Saraiva (FFUP) – 
ongoing studies. 
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Figure 51: Concentration-response curves for the effects of flavonoids Biso1, Brop1 and Bali1 on the growth 
of yeast expressing human procaspase-3 (A) or -7 (B), for 24 hours treatment. The percentage of drug-
induced growth inhibition was estimated considered 100% growth the number of CFU obtained with DMSO 
only. Data are mean ± SEM of six independent experiments; values significantly different from DMSO are 
indicated (*p=0.01, **p=0.001; unpaired student t’ test). 
 
 
The results indicate that compounds Biso1, Brop1 and Bali1, induced growth 
inhibition in yeast cells expressing procaspase-7 at 0.1 - 15 µM (Figure 51, B), with the 
maximal effect achieved at 10 µM for Brop1 and Bali1 and 1 µM for Biso1, without 
interfering with the growth of control yeast (data not shown). Interestingly, the effect of 
these compounds was less pronounced in yeast cells expressing procaspase-3 (Figure 
51, A). The comparison of the concentration-response curves for the effect of flavonoid 
Biso1 here reported with those reported for the baicalein derivative FP2 175, revealed that 
at the concentration of 1 µM (minimum concentration for which the maximal effect was 
achieved for Biso) the percentage of inhibition for Biso1 (about 30 %) was higher than 
the percentage of inhibition obtained for FP2 (about 8 %), suggesting that Biso1 was 
more potent than FP2.  
For procaspase-7, the GI25 values was obtained from concentration–response 
curves (Table 19). 
 
 
 
 
 
 
A B 
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Table 19: GI25 values obtained for PAC-1 and flavonoids Biso1, Brop1 and Bali1. 
 
Compounds 
GI25 
procaspase-3 procaspase-7 
PAC-1 16.6 ± 2.87 24.5 ± 4.82 
Biso1 ND 1.2 ± 2.26** 
Brop1 ND 12.5 ± 4.91 
Bali1 ND 9.3 ± 2.23* 
GI25 values correspond to the concentration that caused 25% growth 
inhibition of yeast cells expressing procaspase-3 or -7 after treatment 
with 0.1 - 15 μM flavonoids Biso1, Brop1 and Bali1, and 0.1 - 50 μM 
PAC-1 (positive control). Data are mean ± SEM of six independent 
experiments.; values significantly different from PAC-1 are indicated 
(*p=0.01, **p=0.001; unpaired ). ND – Not determined. 
 
The GI25 revealed that all tested flavones were more potent than PAC-1, being 
compound Biso1, the most potent derivative. Additionally, contrary to PAC-1 that 
activates both procaspases-3 and -7, the results seggested that all tested flavonoids 
appear to be selective for procaspase-7. 
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3.4. Docking study 
 
An in silico docking study was performed using executioner procaspases-3, -6, and -
7 as targets, and the derivatives already tested in the biological assays (Biso1, Brop1 
and Bali1) as potential ligands. In addition to that compounds, docking studies were also 
performed for the baicalein derivative FP2, already reported as a procaspase-7 
activator175. Docking scores were obtained, which consist of approximations of the free 
energy ΔG of the ligand-macromolecule complex. In this computational study, a series of 
compounds already described in the literature as procaspases modulators189,190,190 
(Figure 52) were used as positive controls. 
 
 
Figure 52: Structures of the positive controls used in the docking study. 
 
The obtained docking scores are represented in Table 20. 
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Table 20: Docking scores (Kcal.mol-1) for procaspase activators described in the literature and derivatives 
Biso1, Brop1 and Bali1. 
 Procaspase-3 Procaspase-7 Procaspase-6 
Controls 
115*  -6.1  
116* -7.6 -6.1  
117*  -6.4  
118*   -9 
119*   -9 
44* -9  -9.9 
120*   -11.4 
121*   -11.4 
122* -7.1   
Tested 
compounds 
FP2 -7.3 -7.7 -9 
Biso1 -7.2 -7.7 -8.7 
Brop1 -6.7 -6.9 -8.7 
Bali1 -6.9 -6.2 -8.7 
*used as positive controls for one, two, or three of the tested procaspases, according to the activation capacity 
previously described in the literature for those targets189,190,190. 
 
Considering procaspase-3, compounds 116, 44 and 122 were used as positive 
controls (Table 20 and Figure 53). By analysis of the obtained docking results, in general 
it was found that all positive controls, particularly compound 1541 (44), had a lower 
docking score and thus formed a more stable complex with procaspase-3 than the 
synthesized compounds. However, Biso1 and FP2 exhibited a ΔG value (-7.2 and 7.3 
Kcal/mol, respectively) similar to the positive control 122, suggesting also the formation of 
a stable complex with procaspase-3.  
For procaspase-7, Biso1, Brop1, and Bali1 revealed a more negative docking 
scores (-7.1, -6.9, and -6.2 Kcal/mol, respectively) than the known activators (compounds 
115- 117 and Figure 54). As with procaspase-3, among the tested compounds Biso1 and 
FP2 are predicted to form more stable complexes with procaspase-7. In addition, both 
derivatives are predicted to bind with the same affinity, as a similar docking score was 
observed for both derivatives. Pereira et al. (2014) verified that FP2 was evolved in the 
activation of procaspase-7 and inhibited the growth of HL-60 and MCF-7 human tumor 
cells175. Therefore, the results obtained for this docking study are in accordance to the 
results already reported.175 Furthermore, a correlation between ΔG and GI25 can be 
observed for derivatives Biso1, Brop1, and Bali1. Indeed, for procaspase-7, among the 
tested compounds Biso1 was the most potent compound with a GI25 value of 1.3 ± 2.2 
µM.  
In vitro studies were not performed for procaspase-6. However, it is important to 
study in silico possible interactions in order to understand if there is the possibility of 
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activation of procaspases-6 by these compounds. The analysis of the results for 
procaspase-6 show that that the prenylated (FP2) and alkylated derivatives of baicalein 
(Biso1, Brop1 and Bali1) have the same (-9 Kcal/mol) or similar (-8.7 Kcal/mol) docking 
scores as controls 117 and 118 (Table 20, Figure 55). However, both synthesized 
compounds and FP2 had higher ΔG values than other known activators described in the 
literature (120, 121 and 44; Table 20, Figure 55). 
In addition to the docking scores, it is important to analyze the possible polar 
interactions established between the tested compounds and procaspases. In Figure 56, 
Figure 57 and Figure 58, the most stable docking conformations of tested compounds 
into procaspase-3, -7 and -6, and polar interactions are represented. 
 
 
 
 
 
 
A 
B 
C 
Figure 53: Compound 122 (A), 116 (B) and 44 (1541) (C) docked into procaspase-3. Small molecules are 
represented as blue sticks, and procaspase-3 is represented as surface. Carbon, oxygen, nitrogen and 
sulphur atoms of the target are represented in green, red, blue, and yellow, respectively. Polar interactions 
are represented as yellow broken line. 
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Figure 55: compound 118 (A), 119 (B), 120 (C), 121 (D) and 44 (1541) (E) docked into procaspase-6. 
Small molecules are represented as blue sticks, and procaspase-6 is represented as surface. Carbon, 
oxygen, nitrogen and sulphur atoms of the target are represented in green, red, blue, and yellow, 
respectively. Polar interactions are represented as yellow broken line. 
Figure 54: compound 115 (A), 117 (B) and 116 (C) docked into procaspase-7. Small molecules are 
represented as blue sticks, and procaspase-7 is represented as surface. Carbon, oxygen, nitrogen and 
sulphur atoms of the target are represented in green, red, blue, and yellow, respectively. Polar interactions 
are represented as yellow broken line. 
A 
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C 
Figure 56: Interactions of Biso1 (A) Brop1 (B) and Bali1 (C) (blue sticks) with residues in the 
allosteric site of procaspase-3. Polar interactions are represented as yellow broken lines. Carbon, 
oxygen, nitrogen and sulphur atoms of the target are represented in green, red, blue, and yellow, 
respectively. 
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A 
Figure 57: Interactions of Biso1 (A) Brop1 (B) and Bali1 (C) (blue sticks) with residues in the 
allosteric site of procaspase-7. Polar interactions are represented as yellow broken lines. Carbon, 
oxygen, nitrogen and sulphur atoms are represented in green, red, blue, and yellow, respectively. 
B 
C 
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A 
B 
C 
Figure 58: Interactions of Biso1 (A) Brop1 (B) and Bali1 (C) (blue sticks) with residues in the 
allosteric site of procaspase-6. Polar interactions are represented as yellow broken lines. Carbon, 
oxygen, nitrogen and sulphur atoms are represented in green, red, blue, and yellow, respectively. 
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All alkylated derivatives (Biso1, Brop1 and Bali1) of baicalein (B) establish polar 
interactions with procaspase-3, -7, and -6 allosteric sites. The different residues involved 
in polar interaction are listed in Table 21. 
 
Table 21: Residues of procaspases-3, -7, and -6 involved in polar interactions with alkylated derivatives 
(Biso1, Brop1 and Bali1). 
Tested 
compounds 
Procaspase-3 Procaspase-7 Procaspase-6 
Biso1 GLU 124 ILE 886 TYR 199 
Brop1 
GLU 124 
TYP 197 
ARG 164 
ILE 886 
GLU 114 
THP 199 
 
Bali1 TYR 197 
THP 333 
ARG 318 
ARG 266 
GLU 214 
THP 199 
 
 
 
Biso1 is the most active procaspase activator both in vitro and in silico. Despite not 
containing the largest number of polar interactions in silico. Nonetheless, it is necessary 
not to disregard the non-polar interactions. Besides establishing polar interactions, the 
isopentoxyl group allows a more favorable orientation and a deeper insertion of the 
molecule into the allosteric groove of the target, as well as the establishment of additional 
van der Waals interactions with the hydrophobic cavity. 
Once Biso1 showed to be the most active derivative, we decided to make an in 
silico docking study to predict the procaspases modulatory activity of other synthesized 
derivatives possessing a 7-isopentyloxy group (derivatives Hiso and Ciso) (Table 22).  
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Table 22: Docking scores (Kcal.mol-1) for modulators described in the literature and alkylated derivatives of 
baicalein (Biso1), 3,7-dihydroxyflavone (Hiso) and chrysin (Ciso). 
 Procaspase-3 Procaspase-7 Procaspase-6 
Controls 
115*  -6.1  
116* -7.6 -6.1  
117*  -6.4  
118*   -9 
119*   -9 
44* -9  -9.9 
120*   -11.4 
121*   -11.4 
122* -7.1   
Tested 
compounds 
Biso1 -7.2 -7.7 -8.7 
Hiso -6.8 -9.6 -7.6 
Ciso -7.1 -9.3 -6.3 
*used as positive controls for one, two, or three of the tested procaspases, according to the activation capacity 
previously described in the literature for those targets189,190,190. 
 
By analysis of the results obtained for procaspase-3, it was found that Hiso and 
Ciso had docking scores similar with Biso1. However, for procaspase-6 the results of 
Hiso and Ciso were worse than Biso1. Curiously, in procaspase-7 the compound Hiso 
had the best result and Ciso had a similar result. These results suggest that the hydroxyl 
group in position 6 may be detrimental to the interaction with procaspase-7. Concerning 
procaspase-3, the results suggest that the hydroxyl group in position 5 is important for 
interaction with procaspase-3. Furthermore, concerning modulation of procaspase-6, the 
presence of two hydroxyl groups in C-5 and C-6 in the flavone scaffold seems to be 
associated to a higher modulatory activity than the presence of just one hydroxyl group in 
C-5. 
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Cancer is an increasing concern of our aging society, being responsible for a high 
mortality rate. Thus, cancer has been the focus of a great concern in general society, 
leading to numerous research studies by the scientific community. Considering that the 
resistance to apoptosis is one of the hallmarks of cancer, the search for compounds that 
induce apoptosis may be a key to the discovery of new antitumor agents. 
Caspases are involved in a cascade cellular of events that results in activation of 
initiator caspases and consequently in the activation of effector caspases triggering the 
apoptosis. Thus, the search for modulators of caspases with the ability to promote their 
activation might be an effective strategy to the activation of apoptosis in tumor cells. 
Flavonoids have a wide range of biological activities including antitumor activity. 
Many flavonoids and in particular prenyl- and alkyl-flavonoids were described as inducers 
of apoptosis by affecting the expression or activity of a wide range of molecules involved 
in apoptosis pathways, namely caspases. However, the reports about the direct activation 
of caspases by flavonoids are scarce and recent.  
The current work allowed the synthesis and identification of twenty-six flavonoids, 
being sixteen described for the first time, using MAOS methodologies. For three 
synthesized alkylated flavonoids (Biso1, Brop1 and Bali1) their ability to modulate the 
activity of procaspases-3 and -7 was evaaluated, using yeast-based assays. For bioactive 
compounds were performed docking studies with procaspases-3,-6 and -7. 
Considering the aims proposed for this dissertation, it is possible to conclude that 
the synthesis of alkylflavonoids by molecular modification of three naturally occurring 
compounds using non-classic methodologies (MAOS) were successfully accomplished. 
However other strategies to obtain these derivatives with a higher yield should be 
investigated in the future. All tested compounds revealed to be procaspase-7 activators, 
particularly Biso1, which showed a lower GI25 value (1.2 ± 2.26 µM) than the positive 
control, PAC-1 (24.5 ± 4.82 µM). Futher studies must be perform in order to evaluate their 
potency and selectivity for procaspases-3, -6 and -7, particularly in comparison to that 
obtained with their starting materials. 
The results presented in this dissertation also suggest that the suitable alkylation of 
flavonoid scaffolds may result in interesting derivatives with the ability to modulate the 
procaspases activity, which deserve further studies in order to confirm the results obtained 
in the yeast cell model. In the future it would be also important to investigate the 
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procaspases modulatory activity of other synthesized compounds using yeast cell assays 
and assays with tumor cell lines to establish structure-activity relationship (SAR). 
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5.1 Chemistry 
 
5.1.1. Synthesis  
 
5.1.1.1. General methods 
 
MW reactions were performed using a glassware setup for atmospheric-pressure 
reactions and a 100 mL or 30 ml Teflon reactor (internal reaction temperature 
measurements with a fiber-optic probe sensor) and were carried out using an Ethos 
MicroSYNTH 1600 Microwave Labstation from Milestone. 
All the reactions were monitored by thin-layer chromatography (TLC). 
Purifications of compounds were carried out by flash chromatography using 
Macherey-Nagel silica gel 60 (0.04-0.063 mm), preparative TLC using Macherey-Nagel 
silica gel 60 (GF254) plates, and crystallization. 
Melting points were obtained in a Köfler microscope and are uncorrected. 
IR spectra were obtained in KBr microplate in a FTIR spectrometer Nicolet iS10 
from Thermo Scientific with Smart OMNI-Transmisson accessory (Software OMNIC 8.3). 
1H and 13C NMR spectra were taken in CDCl3 at r.t., on Bruker Avance 300 and 500 
instruments (300.13 MHz for 1H and 75.47 MHz for 13C). Chemical shifts are expressed in 
δ (ppm) values relative to tetramethylsilane (TMS) used as an internal reference; 13C NMR 
assignments were made by 2D (HSQC and HMBC) NMR experiments (long-range 13C-1H 
coupling constants were optimized to 7 Hz). 
The commercial available reagents were purchased from Sigma Aldrich Co. 
Analytical HPLC-DAD analyses were performed on a SpectraSYSTEM (Thermo 
Fisher Scientific, Inc, USA) equipped with a P4000 pump, an AS3000 autosampler and a 
diode array detector UV8000. The separation was carried out on a 250 x 4.6 mm i.d. 
FortisBIO C18 (5 µm) (FortisTM Technologies Ltd, Cheshire, UK). LC analysis was 
performed by isocratic elution using a mixture of MeOH:H2O:MeCO2H (50:50:1 v/v/v) or 
(95:5:1) as mobile phase and the flow rate was set at 1 mL/min. The injected volume was 
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20 µL and the eluent was monitored at 275 nm. ChromQuest 5.0 (version 3.2.1) software 
(Thermo Fisher Scientific Inc.) managed chromatographic data. Methanol (HPLC grade) 
was obtained from Carlo Erba Reagents, (Val de Reuil, Italy), acetic acid (HPLC grade) 
was obtained from Romil Pure Chemistry (Cambridge, UK) and HPLC grade water 
obtained from a Simplicity® UV Ultrapure Water System, Millipore Corporation, USA. Prior 
to use, mobile phase solvents were degassed in an ultrasonic bath for 15 min.  
All commercially available reagents were purchased from Sigma Aldrich Co. 
Reagents and solvents were purified and dried according to the usual procedures 
described elsewhere.191 The following materials were synthesized and purified by the 
described procedures. 
 
5.1.1.2. Optimization of baicalein alkylation 
 
5.1.1.2.1. HPLC-DAD analysis and quantification 
 
The HPLC-DAD analyses of Biso1 and baicalein (B) was performed by isocratic 
elution using a mixture of MeOH:H2O:MeCO2H (50:50:1 v/v/v). The analyses of Biso2 
was performed by isocratic elution using a mixture of MeOH:H2O:MeCO2H (95:5:1 v/v/v). 
Calibration curves for Biso1 (5, 10, 25, 30, 50, 100, 150 and 200 µg/mL), Biso2 (5, 10, 
25, 30 and 50ug/mL) and baicalein (B) (25, 30, 50, 100, 150 and 200 µg/ mL) were 
prepared by injecting, in triplicate, different concentrations of standard samples, recording 
their peak areas and plotting peak areas vs concentration of the standard. Calibration 
curves exhibited good linear regressions (y = 195215x, r2 = 0.9899 for Biso1 (Rt = 48 
min), y = 146214x, r2 = 0.9721 for Biso2 (Rt = 7 min) and y = 192828x; r2 = 0.9969 for B 
(Rt = 28 min)). 
 
5.1.1.2.2. Optimization of reactional time 
 
Six independent mixtures of baicalein (B) (0.020 g, 0.074 mmol), isopentyl iodide 
(0.118 mmol) and anhydrous K2CO3 (0.052 g, 0.37 mmol) in anhydrous acetone (11 mL) 
were submitted to microwave irradiation at 200 W of power. The final temperature was 60 
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°C and the total irradiation time was 10, 20, 30, 40, 50 or 60 min. After cooling, the solid 
was filtered and the solvent removed under reduced pressure to afford the crude product. 
The solid obtained was dissolved in methanol and, without purification, was analyzed by 
HPLC-DAD, according to 5.1.1.2.1. 
 
5.1.1.2.3. Optimization of the amount of the alkylating agent 
 
A mixture of baicalein (B) (0.020 g, 0.074 mmol), isopentyl iodide (0.059, 0.089, 
0.118 or 0.148 mmol) and anhydrous K2CO3 (0.052 g, 0.37 mmol) in anhydrous acetone 
(11 mL) was submitted to microwave irradiation at 200 W of power. The final temperature 
was 60 °C and the total irradiation time was 20 min. After cooling, the solid was filtered 
and the solvent removed under reduced pressure to afford the crude product. The solid 
obtained was dissolved in methanol and, without purification, was analyzed by HPLC-
DAD, according to 5.1.1.2.1. 
 
5.1.1.3. Derivatives of baicalein 
 
5.1.1.3.1. Alkylated derivatives of baicalein 
 
A mixture of baicalein (B) (0.20 g, 0.74 mmol), isopentyl / butyl / propyl / allyl / ethyl / 
methyl iodide (1.18 mmol) and anhydrous K2CO3 (0.55 g, 3.7 mmol) in anhydrous acetone 
(60 mL) was submitted to successive 30 min of microwave irradiation at 200 W of 
potency. The final temperature was 60 °C and the total irradiation time was 2h, except for 
the reaction with isopentyl iodide, for which the reaction time was 3 h. After cooling, the 
solid was filtered and the solvent removed under reduced pressure to afford the crude 
product. The yellow-orange solid obtained was dissolved in acetone and purified as 
described below. 
 
5,6-dihydroxy-7-(isopentyloxy)-2-phenyl-4H-chromen-4-one (Biso1). Purified by 
flash chromatography (SiO2; n-hexane: EtOAc, 7:3). Yield: 5.6 %; mp 175-178 ºC; IR (kBr) 
ʋmax: 3600-3300, 2955, 2921, 2854, 1657, 1489, 1477, 1450, 1115 cm-1; 1H NMR (CDCl3, 
300.13 MHz) δ= 7.91-7.88 (2H, m, H-2’, 6’), 7.54-7.52 (3H, m, H-3’, 4’, 5’), 6.69 (1H, s, H-
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3), 6.62 (1H, s, H-8), 5.35 (OH, s, H-6), 4.18 (2H, t, J=6.6, H-1’’), 1.93-1.77 (2H, m, H-2’’), 
1.29-1.23 (1H, m, H-3’’), 1.01 (6H, d, J=6.3, H-4’’,5’’); 13C NMR (CDCl3, 75.47 MHz) δ= 
182.7 (C4), 164.0 (C2), 152.3 (C7), 150.7 (C8a), 145.6 (C5), 131.8 (C4’), 131.5 (C1’), 
129.7 (C6), 129.1 (C3’, 5’), 126.2 (C2’, 6’), 106.0 (C4a), 105.4 (C3), 91.0 (C8), 68.0 (C1’’), 
37.5 (C2’’), 29.7 (C3’’), 22.7 (C4’’), 22.6 (C5’’). 
 
5-hydroxy-6,7-bis(isopentyloxy)-2-phenyl-4H-chromen-4-one (Biso2). Purified 
by flash chromatography (SiO2; n-hexane: EtOAc, 9:1) followed by preparative TLC (SiO2; 
n-hexane: EtOAc, 8:2). Yield: 0.6 %; mp 85-87 ºC; IR (kBr) ʋmax: 3600-3300, 2957, 2922, 
2851, 1653, 1559, 1497, 1457, 1419 cm -1; 1H NMR (CDCl3, 300.13 MHz) δ= 12.61 (OH, 
s, H-5), 7.91-7.88 (2H, m, H-2’, 6’), 7.54-7.52 (3H, m, H-3’, 4’, 5’), 6.67 (1H, s, H-3), 6.67 
(1H, s, H-3), 6.56 (1H, s, H-8), 4.12 (2H, t, J=6.5, H-1’’), 4.06 (2H, t, J=6.9, H-1’’’), 1.96-
1.84 (2H, m, H-3’’,3’’’), 1.79 (2H, q, J=6.6, H-2’’), 1.69 (2H, q, J=6.8, H-2’’’), 1.00 (6H, d, 
J=6.5, H-4’’, H-5’’) 0.97 (6H, d, J=6.6, H-4’’’,5’’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.7 
(C4), 163.9 (C2), 158.9 (C7), 153.3 (C8a), 145.7 (C5), 131.9 (C6), 131.7 (C1’), 129.1 (C3’, 
C5’), 126.2 (C2’, 6’), 106.3 (C4a), 105.6 (C3), 91.2 (C8), 71.8 (C1’’’), 67.5 (C1’’), 38.9 
(C2’’’), 37.6 (C2’’), 29.8 (C3’’’), 29.3 (C3’’), 22.7 (C4’’’), 22.6 (C4’’,5’’’), 22.5 (C5’’). 
 
7-butoxy-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (Butil1). Purified by flash 
chromatography (SiO2; petroleum ether: EtOAc, 7:3). Yield: 5.7%; mp 169-172 ºC; IR 
(kBr) ʋmax: 3600-3300, 2956, 2923, 2873, 1655, 1502, 1584, 1464, 1451, 1191 cm-1; 1H 
NMR (CDCl3, 300.13M Hz) δ= 7.91-7.87 (2H, m, H-2’, 6’), 7.54-7.52 (3H, m, H-3’, 4’, 5’), 
6.68 (1H, s, H-3), 6.61 (1H, s, H-8), 4.16 (2H, t, J=6.6, H-1’’), 1.94-1.85 (2H, m, H-
2’’),1.61-1.48 (2H, m, H-3’’), 1.02 (3H, t, J=7.4, H4’’); 13C NMR (CDCl3, 75.47 MHz) δ= 
182.7 (C4), 164.0 (C2), 152.3 (C7), 150.7 (C8a), 145.7 (C5), 131.8 (C4’), 131.5 (C1’), 
129.7 (C6), 129.1 (C3’, 5’), 126.3 (C2’, 6’), 106.0 (C4a), 105.4 (C3), 91.1 (C8), 69.3 (C1’’), 
31.0 (C2’’), 19.2 (C3’’), 13.8 (C4’’). 
 
6,7-dibutoxy-5-hydroxy-2-phenyl-4H-chromen-4-one (Butil2). Purified by flash 
chromatography (SiO2; petroleum ether: EtOAc, 9:1). Yield: 0.5 %; mp 103-106 ºC; IR 
(kBr) ʋmax: 3600-3300, 2961, 2925, 2851, 1657, 1497, 1457, 1419, 1121 cm-1; 1H NMR 
(CDCl3, 300.13 MHz) δ= 7.91-7.88 (2H, m, H-2’, 6’), 7.54-7.52 (3H, m, H-3’, 4’, 5’), 6.67 
(1H, s, H-3), 6.55 (1H, s, H-8), 4.09 (2H, t, J=6.5, H-1’’), 4.05 (2H, t, J=6.6, H-1’’’), 1.93-
1.83 (2H, m, H-2’’), 1.82-1.73 (2H, m, H-2’’’), 1.62-1.48 (4H, m, H-3’’,3’’’), 1.02 (3H, t, J=, 
H4’’); 0.97 (3H, t, J=, H-4’’’); 13C NMR (CDCl3,75.47 MHz) δ= 182.7 (C4), 163.8 (C2), 
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158.9 (C7), 153.2 (C8a), 147.4 (C5), 131.8 (C4’), 131.6 (C1’), 132.1 (C6), 129.1 (C3’, 5’), 
126.3 (C2’, 6’), 106.1 (C4a), 105.6 (C3), 91.3 (C8), 73.1 (C1’’’), 68.9 (C1’’), 32.2 (C2’’), 
31.0 (C2’’), 19.2 (C3’’, C3’’’), 13.9 (C4’’’), 13.8 (C4’’). 
 
5,6-dihydroxy-2-phenyl-7-propoxy-4H-chromen-4-one (Brop1). Purified by flash 
chromatography (SiO2; petroleum ether: EtOAc, 8:2). Yield: 3.5%; mp 167-170 ºC; IR 
(kBr) ʋmax: 3600-3300, 2927, 2922, 2851, 1617, 1559, 1489, 1473, 1459, 1458 cm-1; 1H 
NMR (CDCl3, 300.13 MHz) δ= 12.50 (OH, s, H-5), 7.91-7.88 (2H, m, H-2’, 6’), 7.55-7.52 
(3H, m, H-3’, 4’, 5’), 6.69 (1H, s, H-3), 6.61 (1H, s, H-8), 5.37 (OH, s, H-6), 4.12 (2H, t, 
J=6.9, H-1’’), 2.05-1.98 (2H, m, H-2’’), 1.10 (3H, t, J=7.4, H-3’’); 13C NMR (CDCl3, 75.47 
MHz) δ= 182.7 (C4), 164.0 (C2), 152.3 (C7), 150.7 (C8a), 145.6 (C5), 131.7 (C4’),131.6 
(C1’), 129.7 (C6), 129.1 (C3’, 5’), 126.2 (C2’, 6’), 106.0 (C4a), 105.4 (C3), 91.1 (C8), 71.0 
(C1’’), 22.3 (C2’’), 10.4 (C3’’). 
 
5-hydroxy-2-phenyl-6,7-dipropoxy-4H-chromen-4-one (Brop2). Purified by flash 
chromatography (SiO2; petroleum ether: EtOAc, 9:1). Yield: 6.0%; mp 77-80 ºC; IR (kBr) 
ʋmax: 3600-3300, 2965, 2921, 2851, 1657, 1499, 1470, 1458, 1416, 1122 cm-1; 1H NMR 
(CDCl3, 300.13MHz) δ= 12.50 (OH, s, H-5), 7.90-7.88 (2H, m, H-2’, 6’), 7.54-7.52 (3H, m, 
H-3’, 4’, 5’), 6.67 (1H, s, H-3), 6.55 (1H, s, H-8), 4.05 (2H, t, J=6.5, H-1’’), 4.01 (2H, t, 
J=6.7, H-1’’’), 1.96-1.89 (2H, m, H-2’’), 185-1.78 (2H, m, H-2’’’), 1.10 (3H, t, J=7.4, H-3’’), 
1.06 (3H, t, J=7.4, H-3’’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.7 (C4), 163.8 (C2), 158.8 
(C7), 153.2 (C8a),140.0 (C5), 132.0 (C6), 131.7 (C4’),131.4 (C1’), 129.1 (C3’, 5’), 126.2 
(C2’, 6’), 106.1 (C4a), 105.6 (C3), 91.2 (C8), 75.0 (C1’’’), 70.6 (C1’’), 22.7 (C2’’’), 22.3 
(C2’’), 10.5 (C3’’’), 10.4 (C3’’). 
 
7-(allyloxy)-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (Bali1). Purified by flash 
chromatography (SiO2; n-hexane: EtOAc, 7:3). Yield: 4.2%; mp 160-162 ºC; IR (kBr) 
ʋmax: 3600-3300, 2925, 2923, 2854, 1663, 1576, 1489, 1449, 1252 cm-1; 1H NMR (CDCl3, 
300.13 MHz) δ= 13.04 (OH, s, H-5), 7.90-7.87 (2H, m, H-2’, 6’), 7.58-7.49 (3H, m, H-3’, 4’, 
5’), 6.68 (1H, s, H-3), 6.63 (1H, s, H-8), 6.18-6.05 (1H, m, H-2’’), 5.51-5.45 (1H, m, H-3’’a), 
5.41-5.37 (1H, m, H-3’’b), 4.74 (2H, brd, J=5.4, H-1’’); 13C NMR (CDCl3, 75.47 MHz) δ= 
182.6 (C4), 164.1 (C2), 151.7 (C7), 150.5 (C8a), 145.8 (C5), 131.8 (C4’, C2’’), 131.4 
(C1’), 129.8 (C6), 129.1 (C3’, 5’), 126.2 (C2’, 6’), 119.1 (C3’’), 106.1 (C4a), 105.4 (C3), 
91.6 (C8), 70.2 (C1’’). 
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6-(allyloxy)-5,7-dihydroxy-2-phenyl-4H-chromen-4-one (Bali1’). Purified by flash 
chromatography (SiO2; n-hexane: EtOAc, 9:1) followed by preparative TLC (SiO2; n-
hexane: EtOAc, 8:2). Yield: 1.1%; 166-168 ºC; IR (kBr) ʋmax: 3600-3300, 2925, 2923, 
2854, 1664, 1585, 1489, 1451, 1115 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 13.04 (OH, s, 
H-5), 7.90-7.87 (2H, m, H-2’, 6’), 7.56-7.52 (3H, m, H-3’, 4’, 5’), 6.67 (1H, s, H-3), 6.62 
(1H, s, H-8), 6.14-6.01 (1H, m, H-2’’),5.44-5.37 (1H, m, H-3’’a), 5.32-5.28 (1H, m, H-3’’b), 
4.77 (2H, dt, J=3.3,1.2, H-1’’); 13C NMR (CDCl3, 75.47 MHz) δ= 183.0 (C4), 164.1 (C2), 
155.5 (C7), 153.3 (C8a), 152.1 (C5), 133.0 (C2’’), 131.9 (C4’), 131.3 (C1’), 129.1 (C3’, 5’), 
128.7 (C6), 126.3 (C2’, 6’), 120.0 (C3’’), 106.1 (C4a), 105.3 (C3), 93.4 (C8), 73.7 (C1’’). 
 
7-ethoxy-5,6-dihydroxy-2-phenyl-4H-chromen-4-one (Betil1). Purified by flash 
chromatography (SiO2; n-hexane: EtOAc, 9.5:0.5). Yield: 4.5 %; mp 159-161 ºC; IR (kBr) 
ʋmax: 3600-3300, 2952, 2922, 1653, 1559, 1507, 1457, 1189 cm-1; 1H NMR (CDCl3, 
300.13 MHz) δ= 12.55 (OH, s, H-5), 7.91-7.88 (2H, m, H-2’,6’), 7.55-7.53 (3H, m, H-
3’,4’,5’), 6.69 (1H, s, H-3), 6.61 (1H, s, H-8), 5.37 (OH, brs, H-6), 4.24 (2H, q, J=14.0, 7.0, 
H-1’’), 1.55 (3H, t, J=7.0, H-2’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.7 (C4), 164.1 (C2), 
152.2 (C7), 150.7 (C8a), 145.7 (C5), 131.8 (C4’), 131.5 (C1’), 129.7 (C6), 129.1 (C3’, 5’), 
126.3 (C2’, 6’), 106.0 (C4a), 105.5 (C3), 91.1 (C8), 65.2 (C1’’), 14.6 (C2’’). 
 
5,6-dihydroxy-7-methoxy-2-phenyl-4H-chromen-4-one (Bemet1). Purified by 
flash chromatography (SiO2; n-hexane: EtOAc, 9:1) followed by flash chromatography 
(SiO2; n-hexane). Yield: 15 x%; mp 203-205 ºC; IR(kBr) ʋmax: 3600-3300, 2922, 1631, 
1467 cm-1; 1H NMR (CDCl3, 300.13MHz) δ= 12.69 (OH, s, H-5), 7.92-7.89 (2H, m, H-2’, 
6’), 7.55-7.53 (3H, m, H-3’, 4’, 5’), 6.69 (1H, s, H-3), 6.58 (1H, s, H-8), 5.35 (OH, brs, H-6), 
3.94 (3H, s, H-1’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.8 (C4), 164.0 (C2), 153.1 (C7), 
151.1 (C8a), 145.5 (C5), 131.9 (C4’), 131.3 (C1’), 129.7 (C6), 129.1 (C3’, 5’), 126.3 (C2’, 
6’), 106.1 (C4a), 105.7 (C3), 90.7 (C8), 60.9 (C1’’). 
 
5-hydroxy-6,7-dimethoxy-2-phenyl-4H-chromen-4-one (Bemet2). Purified by 
flash chromatography (SiO2; n-hexane: EtOAc, 9.5:0.5) followed by flash chromatography 
(SiO2; n-hexane). Yield: 1.5x%; mp 150-152 ºC; IR(kBr) ʋmax: 3600-3300, 2922, 1634, 
1505, 1457, 1413 cm-1; 1H NMR (CDCl3, 300.13MHz) δ= 12.69 (OH, s, H-5), 7.92-7.85 
(2H, m, H-2’, 6’), 7.57-7.52 (3H, m, H-3’, 4’, 5’), 6.68 (1H, s, H-3), 6.58 (1H, s, H-8), 3.98 
(3H, s, H-1’’), 3.93 (3H, s, H-1’’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.8 (C4), 164.0 (C2), 
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159.0 (C7), 153.4 (C8a), 145.8 (C5), 131.9 (C4’), 131.3 (C1’), 132.7 (C6), 129.1 (C3’, 5’), 
126.3 (C2’, 6’), 106.1 (C4a), 105.7 (C3), 90.7 (C8), 66.9 (C1’’’), 56.4 (C1’’). 
 
5.1.1.4. Derivatives of 3,7-dihydroxyflavone 
 
5.1.1.4.1. Alkylated derivatives of 3,7-dihydroxyflavone 
 
A mixture of 3,7-dihydroxyflavone (H) (0.19g, 0.74mmol), isopentyl / butyl / propyl / 
allyl / ethyl / methyl iodide (1.18 mmol) and anhydrous K2CO3 (0.55 g, 3.7 mmol) in 
anhydrous acetone (60 mL) was submitted to successive 30 min of microwave irradiation 
at 200 W of potency. Total irradiation time was 2h and the final temperature was 60C.  
After cooling, the solid was filtered and the solvent removed under reduced pressure to 
afford the crude product. The yellow-green solid obtained was dissolved in acetone and 
purified as described below. 
 
3-hydroxy-7-(isopentyloxy)-2-phenyl-4H-chromen-4-one (Hiso). Purified by flash 
chromatography (SiO2; petroleum ether: EtOAc, 9.5:0.5) followed by preparative TLC 
(SiO2; n-hexane: EtOAc, 8:2) and crystallization (chloroform: n-hexane). Yield: 12.9 x %; 
mp = 181-184ºC; IR (kBr) ʋmax: 3600-3300, 2958, 2921, 2854, 1605, 1504, 1467, 1452, 
1410, 1260 cm-1; δ= 8.25-8.22 (2H, m, H-2’, 6’), 8.12 (1H, d, J=8.9, H-5), 7.56-7.42 (3H, 
m, H-3’, 4’, 5’), 6.98 (1H, dd, J=8.9, 2.3, H-6), 6.94 (1H, d, J= 2.3, H-8), 4.11 (2H, t, J= 6.6, 
H-1’’), 1.92-1.81 (1H, m, H-3’’), 1.78-1.72 (2H, m, H-2’’), 1.00 (6H, d, J=6.5, H-4’’, 5’’). 13C 
NMR (CDCl3, 75.47 MHz) δ= 172.9 (C4), 163.9 (C7), 157.4 (C8a), 144.1 (C2), 138.1 (C3), 
131.3 (C1’), 129.6 (C4’), 128.6 (C3’, 5’), 127.5 (C2’, 6’), 126.7 (C5), 115.3 (C6), 115.1 
(C4a), 100.3 (C8), 67.2 (C1’’), 37.6 (C2’’), 25.1 (C3’’), 22.6 (C4’’, 5’’). 
 
7-butoxy-3-hydroxy-2-phenyl-4H-chromen-4-one (Hutil1). Purified by flash 
chromatography (SiO2; n-hexane : EtOAc, 9.5;0.5) followed by preparative TLC (SiO2; n-
hexane: EtOAc, 8:2) and crystallization (chloroform: n-hexane) Yield: 9.7 x %; mp= 149-
151ºC ; IR (kBr) ʋmax: 3600-3300, 2958, 2922, 2854, 1604, 1566, 1462, 1452, 1419, 
1250 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 8.25-8.22 (2H, m, H-2’, 6’), 8.13 (1H, d, 
J=8.6, H-5), 7.56-7.43 (3H, m, H-3’, 4’, 5’), 7.00 (1H, dd, J=8.8, 2.3, H-6), 6.95 (1H, d, J= 
2.3, H-8), 4.09 (2H, t, J= 6.5, H-1’’), 1.89-1.80 (2H, m, H-2’’), 1.60-1.47 (2H, m, H-3’’), 1.01 
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(3H, t, J=7.4, H-4’’). 13C NMR (CDCl3, 75.47 MHz) δ= 206.0 (C4), 162.9 (C7), 156.4 (C8a), 
143.1 (C2), 137.1 (C3), 131.3 (C1’), 130.2 (C4’), 128.9 (C3’, 5’), 127.5 (C2’, 6’), 126.5 
(C5), 114.2 (C6), 113.4 (C4a), 99.3 (C8), 67.4 (C1’’), 29.9 (C2’’), 18.2 (C3’’), 12.8 (C4’’). 
 
3,7-dibutoxy-2-phenyl-4H-chromen-4-one (Hutil2). Purified by flash 
chromatography (SiO2; n-hexane : EtOAc, 9.75:0.25). Yield: 7.1 x%; mp= 190-193ºC ; 
IR(kBr) ʋmax: 3600-3300, 2936, 1873, 1623, 1499, 1466, 1447, 1260 cm-1; 1H NMR 
(CDCl3, 300.13 MHz) δ= 8.10-8.07 (2H, m, H-2’, 6’), 8.14 (1H, d, J=8.9, H-5), 7.52-7.49 
(3H, m, H-3’, 4’, 5’), 6.96 (1H, dd, J=8.9, 2.3, H-6), 6.90 (1H, d, J= 2.3, H-8), 4.06 (2H, t, 
J=6.5, H-1’’), 4.02 (2H, t, J=6.5, H-1’’’), 1.87-1.78 (2H, m, H-2’’), 1.73-1.63 (2H, m, H-2’’’), 
1.59-1.49 (2H, m, H-3’’), 1.42-1.32 (2H, m, H-3’’’), 1.00 (3H, t, J=7.4, H-4’’), 0.87 (3H, t, 
J=7.4, H-4’’’). 13C NMR (CDCl3, 75.47 MHz) δ= 174.8 (C4), 163.6 (C7), 157.1 (C8a), 155.3 
(C2), 140.5 (C3), 131.3 (C1’), 130.4 (C4’), 128.3 (C2’, 6’), 128.7 (C3’. C5’), 127.1 (C5), 
114.8 (C6), 113.6 (C4a), 100.3 (C8), 72.6 (C1’’’), 68.4 (C1’’), 32.1 (C2’’’), 31.0 (C2’’), 19.2 
(C3’’’), 19.1 (C3’’), 13.8 (C4’’, 4’’’). 
 
3-hydroxy-2-phenyl-7-propoxy-4H-chromen-4-one (Hrop). Purified by flash 
chromatography (SiO2; petroleum ether: EtOAc, 95:5) followed by preparative TLC (SiO2; 
n-hexane: EtOAc, 8:2) and crystallization (chloroform: n-hexane). Yield: 3.7 x% as yellow 
crystals; mp= 173-174ºC; IR (kBr) ʋmax: 3600-3300, 2970, 1920, 1603, 1576, 1504, 1432, 
1412, 1259 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 8.25-8.22 (2H, m, H-2’, 6’), 8.13 (1H, 
d, J=8.9, H-5), 7.61-7.43 (3H, m, H-3’, 4’, 5’). 7.00 (1H, dd, J= 10.4, 2.3, H-6), 6.97 (1H, d, 
J=2.3, H-8), 4.05 (2H, t, J=6.6, H-1’’), 1.95-1.83 (2H, m, H-2’’), 1.09 (3H, t, J=7.4, H-3’’). 
13C NMR (CDCl3,75.47 MHz) δ= 172.9 (C4), 163.9 (C7), 157.4 (C8a), 144.1 (C2), 138.1 
(C3), 131.3 (C1’),129.9 (C4’), 128.6 (C3’, 5’), 127.5 (C2’, 6’), 126.7 (C5), 115.3 (C6), 
113.6 (C4a), 100.3 (C8), 70.3(C1’’), 22.4 (C2’’), 10.5 (C3’’). 
 
7-(allyloxy)-3-hydroxy-2-phenyl-4H-chromen-4-one (Hali). Purified by flash 
chromatography (SiO2; n-hexane: EtOAc, 9.75:0.25) followed by preparative TLC (SiO2; 
n-hexane: EtOAc, 8:2) and crystallization (chloroform: n-hexane). Yield: 9.3 x%; mp= 144-
146ºC; IR(kBr) ʋmax: 3600-3300, 2999, 2964, 2921, 2847, 1615, 1564, 1503, 1473, 1453, 
1260 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 8.25-8.22 (2H, m, H-2’, 6’), 8.15 (1H, d, 
J=8.9, H-5), 7.03 (1H, dd, J= 8.6, 2.3, H-6), 6.97 (1H, d, J=2.3, H-8), 6.16-6.03 (1H, m, H-
2’’), 5.52-5.44 (2H, m, H-3’’a), 5.40-5.31 (2H, m, H-3’’b), 4.67 (2H, dt, J=5.3, 1.5, H-1’’). 
13C NMR (CDCl3, 75.47 MHz) δ= 172.8 (C4), 163.2 (C7), 157.3 (C8a), 144.1 (C2), 138.1 
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(C3),131.9 (C2’’) 131.2 (C1’), 129.9 (C4’), 128.6 (C3’, 5’), 127.5 (C2’, 6’), 126.8 (C5),118.6 
(C3’’), 115.2 (C6), 100.3 (C8), 69.6 (C1’’). 
 
7-ethoxy-3-hydroxy-2-phenyl-4H-chromen-4-one (Hetil). Purified by flash 
chromatography (SiO2; n-hexane: EtOAc, 9.75:0.25) followed by preparative TLC (SiO2; 
n-hexane: EtOAc, 8:2) and crystallization (chloroform: n-hexane). Yield: 1.7 %; mp=195-
197ºC; IR(kBr) ʋmax: 3600-3300, 2926, 1614, 1504, 1457, 1408, 1262 cm-1; 1H NMR 
(CDCl3, 300.13 MHz) δ= 8.25-8.22 (2H, m, H-2’, 6’), 8.13 (1H, d, J=8.9, H-5),7.56-7.43 
(3H, m, H-3’, 4’, 5’), 6.99 (1H, dd, J= 8.9, 2.1, H-6), 6.95 (1H, d, J=2.4, H-8), 4.17 (2H, q, 
J= 6.9, H-1’’), 1.50 (3H, t, J=6.9, H-2’’). 13C NMR (CDCl3, 75.47 MHz) δ= 172.9 (C4), 
163.7 (C7), 157.4 (C8a), 144.1 (C2), 138.1 (C3), 131.3 (C1’), 129.9 (C4’), 128.8 (C3’, 5’), 
127.5 (C2’, 6’), 126.7 (C5), 115.2 (C6), 114.4 (C4a), 100.3 (C8), 64.3 (C1’’), 14.6 (C2’’). 
 
3-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one (Hemet). Purified by flash 
chromatography (SiO2; n-hexane: EtOAc, 9.75:0.25) followed by preparative TLC (SiO2; 
n-hexane: EtOAc, 8:2) and crystallization (chloroform: n-hexane). Yield: 9.2x%; mp 180-
182  ºC; IR(kBr) ʋmax: 3600-3300, 2922, 1622, 1508, 1456, 1401, 1262 cm-1; 1H NMR 
(CDCl3, 300.13 MHz) δ= 8.24-8.21 (2H, m, H-2’, 6’), 8.13 (1H, d, J=8.9, H-5), 7.55-7.42 
(3H, m, H-3’, 4’, 5’), 6.99 (1H, dd, J= 8.9, 2.3, H-6), 6.94 (1H, d, J=2.3, H-8), 3.93 (3H, s, 
H-1’’). 13C NMR (CDCl3, 75.47 MHz) δ= 172.8 (C4), 164.3 (C7), 157.4 (C8a), 144.2 (C2), 
138.1 (C3), 131.2 (C1’), 129.9 (C4’), 128.6 (C3’, 5’), 127.5 (C2’, 6’), 126.8 (C5), 115.2 
(C6), 114.9 (C4a), 99.8 (C8), 53.9 (C1’’). 
 
5.1.1.4.2. Prenylated derivative of 3,7-dihydroxyflavone 
 
A mixture of 3,7-dihydroxyflavone (H) (0.188 g, 0.74 mmol), prenyl bromide (171µl, 
1.48 mmol), potassium iodide (0.012 g, 0.074 mmol)  and anhydrous K2CO3 (0.55g, 
3.7mmol,) in anhydrous acetone (60ml) was submitted to successive 15 min of microwave 
irradiation at 200 W of potency. Total irradiation time was 45 min and the final temperature 
was 60 °C. After cooling, the solid was filtered and the solvent removed under reduced 
pressure to afford the crude product. The solid obtained was dissolved in acetone and 
purified by flash chromatography (SiO2; petroleum ether: EtOAc, 9.75:0.25) and then by 
preparative TLC (SiO2; n-hexane: EtOAc, 7:3) and crystallization (chloroform: n-hexane). 
One compound was obtained (Hrep). 
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3-hydroxy-7-((3-methylbut-2-en-1-yl)oxy)-2-phenyl-4H-chromen-4-one (Hrep). 
Yield: 7.4 x%; mp= 174-176ºC; IR (kBr) ʋmax: 3600-3300, 2974, 2920, 2854, 1613, 1566, 
1463, 1451, 1408, 1258 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 8.25-8.22 (2H, m, H-2’ H-
6’), 8.13 (1H, d, J=8.7, H-5), 761-7.44 (3H, m, H-3’ H-4’ H-5’), 7.02 (1H, d, J=2.3, H-6) ou 
6.98 (1H, dd, J= 6.2, 2.2, H-6), 7.01 (1H, dd, J=8.8, 2.3, H-8) ou 6.97 (1H, d, J=2.2, H-8), 
5.56-5.51 (1H, m, H-2’), 4.64 (2H, d, J=6.7, H-1’’), 1.84 (3H, s, H-4’’), 1.80 (3H, s, H-5’’). 
13C NMR (CDCl3, 75.47 MHz) δ= 207.0 (C4), 163.6 (C7), 157.4 (C8a), 144.2 (C2), 139.5 
(C3), 131.3 (C1’), 129.9 (C4’), 128.6 (C3’, 5’), 127.5 (C2’, 6’), 126.7 (C5), 118.5 (C2’’), 
115.4 (C6), 114.7 (C4a), 100.6 (C8), 65.5 (C1’’), 31.0 (C3’’), 25.9 (C4’’’), 18.3 (C5’’). 
 
5.1.1.5. Derivatives of chrysin 
 
5.1.1.5.1. Alkylated derivatives of chrysin 
 
A mixture of chrysin (C) (0.188g, 0.74mmol), isopentyl / butyl / propyl / allyl / ethyl / 
methyl iodide (1.18 mmol) and anhydrous K2CO3 (0.55 g, 3.7 mmol) in anhydrous acetone 
(60 mL) was submitted to successive 30 min of microwave irradiation at 200 W of 
potency. Total irradiation time was 90 min and the final temperature was 60 °C.  After 
cooling, the solid was filtered and the solvent removed under reduced pressure to afford 
the crude product. The solid obtained was dissolved in acetone and purified by flash 
chromatography (SiO2; n-hexane: EtOAc; 9:1). 
 
5-hydroxy-7-(isopentyloxy)-2-phenyl-4H-chromen-4-one (Ciso). Yield: 30%; mp 
129-132 ºC; IR (kBr) ʋmax: 3600-3400, 2956, 2921, 1851, 1662, 1588, 1452, 1169 cm-1; 
1H NMR (CDCl3, 300.13 MHz) δ= 12.71 (OH, s, H-5), 7.90-7.87 (2H, m, H-2’, 6’), 7.55-
7.52 (3H, m, H-3’, 4’, 5’), 6.67 (1H, s, H-3), 6.50 (1H, d, J=2.2, H-8), 6.37 (1H, d, J=2.2, H-
6), 4.06 (2H, t, J=6.6, H-1’’), 1.92-1.78 (1H, m, H-3’’), 1.75-1.68 (2H, m, H-2’’), 0.98 (6H, d, 
J=6.5, H-4’’, 5’’). 13C NMR (CDCl3, 75.47 MHz) δ= 182.5 (C4), 168.2 (C7), 163.9 (C2), 
162.1 (C5), 131.8 (C1’), 129.1 (C3’, 5’), 126.3 (C2’, 6’), 105.9 (C3), 98.6 (C6), 93.1 (C8), 
67.1 (C1’’), 37.6 (C2’’), 25.0 (C3’’), 22.5 (C4’’, 5’’). 
 
5-hydroxy-2-phenyl-7-propoxy-4H-chromen-4-one (Cutil). Yield: 29%; mp 145-
148 ºC; IR (kBr) ʋmax: 3600-3400, 2952,2933, 2868, 1664, 1589, 1569, 1450, 1442, 
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1274, 1170 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 7.87-7.84 (2H, m, H-2’, 6’), 7.52-7.50 
(3H, m, H-3’, 4’, 5’), 6.63 (1H, s, H-3), 6.47 (1H, d, J=2.2, H-8), 6.34 (1H, d, J=2.2, H-6), 
4.02 (2H, t, J=6.5, H-1’’), 1.84-1.75 (2H, m, H-2’’), 1.56-1.44 (2H, m, H-3’’), 0.99 (3H, t, 
J=7.4, H-4’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.4 (C4), 165.2 (C7), 163.8 (C2), 162.1 
(C5), 157.8 (C8a), 131.8 (C4’), 131.3 (C1’), 129.1 (C3’, 5’), 126.2 (C2’, 6’), 105.8 (C3), 
105.5 (C4a), 98.6 (C6), 93.0 (C8), 68.4 (C1’’), 31.0 (C2’’), 19.2 (C3’’), 13.8 (C4’’). 
 
5-hydroxy-2-phenyl-7-propoxy-4H-chromen-4-one (Crop). Yield: 22%; mp 132-
135 ºC; IR (kBr) ʋmax: 3600-3400, 2964, 2920, 2874, 1661, 1585, 1569, 1507, 1451, 
1173 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 12.70 (OH, s, H-5), 7.90-7.87 (2H, m, H-2’, 
6’), 7.56-7.49 (3H, m, H-3’, 4’, 5’), 6.66 (1H, s, H-3), 6.50 (1H, d, J=2.2, H-8), 6.37 (1H, d, 
J=2.2, H-6), 4.00 (2H, t, J=6.6, H-1’’), 1.90-1.79 (2H, m, H-2’’), 1.06 (3H, t, J=7.4, H-3’’). 
13C NMR (CDCl3,75.47 MHz) δ= 182.5 (C4), 165.2 (C7), 163.9 (C2), 162.1 (C5), 157.8 
(C8a), 131.8 (C4’), 131.4 (C1’), 129.1 (C3’, 5’), 126.3 (C2’, 6’), 105.9 (C3), 105.6 (C4a), 
98.6 (C6), 93.1 (C8), 70.2 (C1’’), 22.3 (C2’’), 10.4 (C3’’). 
 
7-(allyloxy)-5-hydroxy-2-phenyl-4H-chromen-4-one (Cali). Yield: 31%; mp 118-
120 ºC; IR (kBr) ʋmax: 3600-3400, 2961, 2920, 2851, 1665, 1586, 1506, 1451, 1203, 
1170 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 12.72 (OH, s, H-5), 7.90-7.88 (2H, m, H-2, 
6’), 7.58-7.51 (3H, m, H-3’, 4’, 5’), 6.68 (1H, s, H-3), 6.53 (1H, d, J=2.3, H-8), 6.40 (1H, d, 
J=2.3, H-6), 6.10-6.02 (1H, m, H-2’’) 5.48-5.44 m (1H, m, H-3’’a), 5.37-5.34 (1H, m, H-
3’’b), 4.63 (2H, dt, J=5.2, 1.4, H-1’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.5 (C4), 164.6 
(C7), 164.0 (C2), 162.2 (C5), 157.8 (C8a), 132.1 (C2’’), 131.9 (C4’), 131.4 (C1’), 129.1 
(C3’, 5’), 126.3 (C2’, 6’), 118.5 (C3’’’), 105.9 (C3), 105.8 (C4a), 98.8 (C6), 93.4 (C8), 69.3 
(C1’’). 
 
7-ethoxy-5-hydroxy-2-phenyl-4H-chromen-4-one (Cetil). Yield: 32%; mp 153-154 
ºC; IR (kBr ) ʋmax: 3600-3400, 2985, 2924, 2852, 1663, 1586, 1509, 1454, 1204, 1173 
cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 7.89-7.86 (2H, m, H-2’,6’), 7.53-7.51 (3H, m, H-3’, 
4’, 5’), 6.65 (1H, s, H-3), 6.48 (1H, d, J=2.2, H-8), 6.35 (1H, d, J=2.2, H-6), 4.10 (2H, q, 
J=7.0, H-1’’), 1.45 (3H, t, J=7.0, H-2’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.5 (C4), 165.0 
(C7), 163.9 (C2), 162.1 (C5), 157.8 (C8a), 131.8 (C4’), 131.3 (C1’), 129.1 (C3’, 5’), 126.3 
(C2’, 6’), 105.8 (C3), 105.6 (C4a), 98.6 (C6), 93.1 (C8), 64.2 (C1’’), 14.6 (C2’’).  
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5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one (Cemet). Yield: 44%; mp 165-
168 ºC; IR(kBr) ʋmax: 3600-3400, 2923, 2854, 1668, 1588, 1495, 1452, 1436, 1202, 1160 
cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 12.73 (OH, s, H-5), 7.91-7.88 (2H, m, H-2’, 6’), 
7.55-7.52 (3H, m, H-3’, 4’, 5’), 6.67 (1H, s, H-3), 6.51 (1H, d, J=2.2, H-8), 6.38 (1H, d, 
J=2.2, H-6), 3.89 (3H, s, H-1’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.5 (C4), 165.6 (C7), 
164.0 (C2), 162.2 (C5), 157.8 (C8a), 131.9 (C4’), 131.3 (C1’), 129.1 (C3’, 5’), 126.3 (C2’, 
6’), 105.9 (C3), 105.7 (C4a), 98.2 (C6), 92.7 (C8), 55.8 (C1’’). 
 
5.1.1.5.2. Prenylated derivative of chrysin 
 
A mixture of Chrysin (C) (0.188 g, 0.74 mmol), prenyl bromide (171 µL, 1.48 mmol), 
potassium iodide (0.012 g, 0.074 mmol)  and anhydrous K2CO3 (0.55 g, 3.7 mmol) in 
anhydrous acetone (60 mL) was submitted to successive 30 min of microwave irradiation 
at 200 W of potency. Total irradiation time was 90 min and the final temperature was 60 
°C. After cooling, the solid was filtered and the solvent removed under reduced pressure 
to afford the crude product. The yellow-orange solid obtained was dissolved in acetone 
and purified by flash chromatography (SiO2; n-hexane: EtOAc; 9:1). One compound was 
isolated (Crep). 
 
5-hydroxy-7-((3-methylbut-2-en-1-yl)oxy)-2-phenyl-4H-chromen-4-one (Crep):  
Yield: 67%; mp 104-107 ºC; IR (kBr) ʋmax: 3600-3400, 2967, 2917, 2853, 1659, 1588, 
1504, 1449, 1178 cm-1; 1H NMR (CDCl3, 300.13 MHz) δ= 12.69 (OH, s, H-5), 7.86-7.82 
(2H, m, H-2’, 6’), 7.51-7.48 (3H, m, H-3’, 4’, 5’), 6.61 (1H, s, H-3), 6.46 (1H, d, J=2.2, H-8), 
6.33 (1H, d, J=2.2, H-6), 5.48 (1H, t, J=6.7, H-2’’), 4.56 (2H, d, J=6.9, H-1’’), 1.81 (3H, s, 
H-4’’), 1.76 ( 3H, s, H-5’’); 13C NMR (CDCl3, 75.47 MHz) δ= 182.4 (C4), 164.9 (C7), 163.8 
(C2), 162.0 (C5), 157.7 (C8a), 139.2 (C3’’), 131.8 (C4’), 131.2 (C1’), 129.0 (C3’, 5’), 126.2 
(C2’, 6’), 118.6 (C2’’), 105.7 (C3), 105.6 (C4a), 98.8 (C6), 93.2 (C8), 65.5 (C1’’), 25.8 
(C4’’), 18.3 (C5’’). 
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5.2 Peak purity 
 
Analytical HPLC-DAD analyses were performed on a SpectraSYSTEM (Thermo 
Fisher Scientific, Inc, USA) equipped with a P4000 pump, a AS3000 autosampler and a 
diode array detector UV8000. The separation was carried out on a 250 x 4.6 mm i.d. 
FortisBIO C18 (5 µm) (FortisTM Technologies Ltd, Cheshire, UK).  
LC analysis was performed by isocratic elution using a mixture of MeOH:H2O:MeCO2H 
(70:30:1 v/v/v) as mobile phase and the flow rate was set at 1 mL/ min. The injected 
volume was 20 µL and the eluent was monitored at 275 nm. The detector was set at a 
wavelength range of 190–800 nm with a spectral resolution of 1 nm. The purity 
parameters included a 95 % active peak region and a scan threshold of 5 mAU. 
ChromQuest 5.0 (version 3.2.1) software (Thermo Fisher Scientific Inc.) managed 
chromatographic data. Methanol (HPLC grade) was obtained from Carlo Erba Reagents 
(Val de Reuil, Italy), acetic acid (HPLC grade) was obtained from Romil Pure Chemistry 
(Cambridge, UK) and HPLC grade water obtained from a Simplicity® UV Ultrapure Water 
System, Millipore Corporation, USA. Prior to use, mobile phase solvents were degassed 
in an ultrasonic bath for 15 min.  
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5.3. Biological activity 
 
5.3.1. Reagents and stock solutions of compounds 
 
Procaspase-activating compound-1 (PAC-1) were purchased from Calbiochem. 
Solutions of compounds were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and 
stored at -20 ºC. Appropriate dilutions of the compounds were freshly prepared with 
culture medium prior to the assays.  Glucose, galactose and glycerol were from Sigma-
Aldrich (Sintra, Portugal). Yeast nitrogen base without amino acids from Difco (Quilaban, 
Sintra, Portugal). Sabouraud Dextrose Agar (SDA) from Liofilchem (Frilabo, Porto, 
Portugal). 
 
5.3.2. Yeast procaspase-3 and -7 assay† 
 
5.3.2.1. Compounds 
 
Details concerning the synthesis of tested flavonoids Biso1, Brop1 and Bali1 are 
described in the chapter III and V.  
 
5.3.2.2. Plasmids 
 
For expression in yeast of procaspase-3 and -7 the expression vectors pGALL-
(LEU2) encoding each human protein under a GAL1-10 promoter were used. 
 
5.3.2.3. Yeast strain, transformation and growth conditions 
 
                                               
† Work developed by the Master student Sofia Salazar under the supervision of Professor Lucília Saraiva (FFUP) – 
ongoing studies. 
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Saccharomyces cerevisiae (strain CG379 Mata, ade5, his2, leu2-112, trp1-289, 
ura3-52) was granted by Yeast Genetic Center, University of California, USA. 
Saccharomyces cerevisiae was transformed using the standard lithium acetate method 
175. For the selection of transformed yeast, cells were grown in glucose minimal selective 
medium with 2% (w/v) glucose, 0.67% (w/v) yeast nitrogen base without amino acids  and 
all the amino acids required for yeast growth (50 µg/ml) except leucine, and incubated at 
30 ºC, under continuous orbital shaking (170 r.p.m.). To induce the expression of human 
proteins, yeast cultures were diluted to 0.05 optical density at 600 nm (OD600) in induction 
selective medium containing 2% (w/v) galactose and 1% glycerol and grown at 30 ºC 
under continuous shaking. The effects of procaspase-3 and -7 on yeast growth were 
analyzed as previously described for the active caspase-3 192. Briefly, yeast cells 
expressing the human protein and control yeast (transformed with the empty vector, 
pGALL) were grown in induction selective medium for up to 24 h for growth curves 
experiments. Yeast growth was analyzed by counting the number of colony-forming units 
per ml (CFU/ml) after 2 days incubation at 30 ºC on Sabouraud Dextrose Agar plates. 
 
5.3.2.4. Effects of the compounds on yeast cell growth 
 
In yeast assays with procaspase-3 and -7, the known activator of caspase-3 and -7, 
PAC-1 33, was used as positive control. To analyze the effect of compounds on yeast cell 
growth, transformed cells were incubated in induction selective medium in the presence of 
0.1–15 µM (for procaspases) compounds, 0.1-50 µM of PAC-1, or DMSO only (0.1%). 
Cells were incubated to approximately 0.3 OD600 (achieved with each transformant 
incubated with DMSO only), and the cell growth was analyzed as described above. For 
each culture, the percentage of drug-induced growth inhibition was estimated considering 
100% growth the number of CFU obtained with yeast incubated with DMSO only.  
 
5.3.2.5. Statistical analysis  
 
For yeast-based assays results were analyzed statistically using the SigmaPlot 
12.00 software and differences between means were tested for significance using the 
unpaired student´s t-test (p < 0.01 or p < 0.001). 
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5.4. Docking study 
 
Structure files for each molecule were created and minimized using the chemical 
structure drawing tool Hyperchem 7.5 (Hypercube, FL, USA). Docking studies were 
performed using Autodock Vina software package (Molecular Graphics Lab, CA, USA). 
The molecular modeling program UCSF Chimera 1.4 was used to prepare the receptor 
(procaspase-3, pdb ID 4JR0; procaspase-6, pdb ID 4NBN; procaspase-7, pdb ID 
1GQF).The allosteric site in the procaspases dimer interface 189 was selected for use in 
docking simulation by building a grid box with the dimentions 25 x 25 x 25 Å. Docking was 
performed by incorporating ligand flexibility, and docking scores were used for analysis. 
PyMol1.3 (Schrödinger , NY, USA) was used for visual inspection of results and graphical 
representations. 
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Table 23: Structures of the synthesized flavonoids and their precursors. 
Structure Name Code 
 
5,6,7-trihydroxy-2-
phenyl-4H-chromen-4-
one 
 
B 
 
5,6-dihydroxy-7-
(isopentyloxy)-2-phenyl-
4H-chromen-4-one 
 
Biso1 
 
5-hydroxy-6,7-
bis(isopentyloxy)-2-
phenyl-4H-chromen-4-
one 
 
Biso2 
 
7-butoxy-5,6-dihydroxy-
2-phenyl-4H-chromen-
4-one 
 
Butil1 
 
6,7-dibutoxy-5-hydroxy-
2-phenyl-4H-chromen-
4-one 
 
Butil2 
 
5,6-dihydroxy-2-phenyl-
7-propoxy-4H-chromen-
4-one 
 
Brop1 
 
5-hydroxy-2-phenyl-6,7-
dipropoxy-4H-chromen-
4-one 
 
Brop2 
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Table23 (contd): Structures of the synthesized flavonoids and their precursors. 
Structure Name Code 
 
7-(allyloxy)-5,6-
dihydroxy-2-phenyl-4H-
chromen-4-one 
 
Bali1 
 
6-(allyloxy)-5,7-
dihydroxy-2-phenyl-4H-
chromen-4-one 
 
Bali1’ 
 
7-ethoxy-5,6-dihydroxy-
2-phenyl-4H-chromen-
4-one 
Betil1 
 
 
5,6-dihydroxy-7-
methoxy-2-phenyl-4H-
chromen-4-one 
Bemet1 
 
 
5-hydroxy-6,7-
dimethoxy-2-phenyl-4H-
chromen-4-one 
Bemet2 
 
 
3,7-dihydroxy-2-phenyl-
4H-chromen-4-one 
H 
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Table23 (contd): Structures of the synthesized flavonoids and their precursors. 
Structure Name Code 
 
 
3-hydroxy-7-(isopentyloxy)-
2-phenyl-4H-chromen-4-
one 
 
Hiso 
 
 
7-butoxy-3-hydroxy-2-
phenyl-4H-chromen-4-one 
 
Hutil1 
 
 
3,7-dibutoxy-2-phenyl-4H-
chromen-4-one 
 
Hutil2 
 
 
3-hydroxy-2-phenyl-7-
propoxy-4H-chromen-4-
one 
 
Hrop 
 
 
7-(allyloxy)-3-hydroxy-2-
phenyl-4H-chromen-4-one 
 
Hali 
 
 
7-ethoxy-3-hydroxy-2-
phenyl-4H-chromen-4-one 
 
Hetil 
 
 
3-hydroxy-7-methoxy-2-
phenyl-4H-chromen-4-one 
 
Hemet 
 
3-hydroxy-7-((3-methylbut-
2-en-1-yl)oxy)-2-phenyl-
4H-chromen-4-one 
 
Hrep 
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Table23 (contd): Structures of the synthesized flavonoids and their precursors. 
Structure Name Code 
 
 
5,7-dihydroxy-2-phenyl-4H-
chromen-4-one 
 
C 
 
5-hydroxy-7-(isopentyloxy)-
2-phenyl-4H-chromen-4-
one 
 
Ciso 
 
 
5-hydroxy-2-phenyl-7-
propoxy-4H-chromen-4-one 
 
Cutil 
 
 
5-hydroxy-2-phenyl-7-
propoxy-4H-chromen-4-one 
 
Crop 
 
 
7-(allyloxy)-5-hydroxy-2-
phenyl-4H-chromen-4-one 
 
Cali 
 
 
7-ethoxy-5-hydroxy-2-
phenyl-4H-chromen-4-one 
 
Cetil 
 
 
5-hydroxy-7-methoxy-2-
phenyl-4H-chromen-4-one 
 
Cemet 
 
5-hydroxy-7-((3-methylbut-
2-en-1-yl)oxy)-2-phenyl-4H-
chromen-4-one 
 
Crep 
 
